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Papillomaviruses are a group of highly specialized, 
transmissible, host and target specific DNA viruses which 
infect the squamous epithelia and cause benign and 
occasionally, malignant hyperplastic, papillomatous and/or 
verrucous proliferations in skin and mucosa of a wide range 
of animals and humans. 1 • 2 • 3 
In vertebrate animals, papillomaviruses produce 
papillomas in the skin of the rabbits which either regress, 
persist or undergo malignant transformation. 4 Also, they 
have the ability to stimulate the dermal fibroblasts 
inducing formation of fibroblastic tumors of the brain, 
polyploid tumors of the urinary bladder in cattle, sarcoma-
like tumors in the skin of the horse, connective tissue 
tumors (fibromas, fibrosarcomas, chondromas) in hamsters and 
fibromas in a type of mice. 5 In the oral cavity of 
vertebrate animals, the papillomavirus is known to cause 
oral papillomas in dogs, which might progress to squamous 
cell carcinomas. 6 The bovine papillomavirus type 4 causes 
alimentary tract papillomatosis in cattle which might become 
malignant, if fed with braken fern7 or immunosuppressed 
with azathioprine. 8 
In humans, papillomaviruses have been identified in 
2 
numerous proliferative disorders including active keratosis, 
bowenoid papulosis, carcinomas of penis and vulva, cervical 
intraepithelial dysplasias, condyloma acuminata, 
epidermodysplasia verruciformis, kerathoacanthomas, low 
grade epithelial dysplasias, melanomas, skin warts, squamous 
and verrucous carcinomas (Bushke-Lowenstein tumor). In the 
oral cavity, human papillomaviruses have been identified in 
condyloma acuminatum, epithelial dysplasias, papillomas, 
warts, focal epithelial hyperplasia, laryngeal papillomas, 
"hairy" leukoplakias, leukoplakias, lichen planus, squamous 
and verrucous carcinomas. 9 •10 • 11 
There are more than 60 types of human papillomavirus 
(HPV) identified so far and more than 10 have been 
identified in oral lesions. 12 The type of human 
papillomavirus determines the histology of the lesion, the 
quantity of virus production and its malignant 
transformation. 13 
The oral squamous papilloma is a generic name that 
includes papillary and verruca! epithelial growths. The 
squamous papilloma is the most common benign epithelial 
tumor of the oral cavity, although some investigators regard 
it as potentially pre-malignant, that can occur at any age, 
but mainly in the third through the fifth decades. Any 
region of the oral mucosa might be affected, but the most 
common sites are the hard-soft palate-uvula complex, dorsum 
and lateral tongue borders and lips. 
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Clinically, the oral squamous papilloma appears as a 
painless, white or pink small (the majority measures 25 to 
30 mm in diameter), usually well circumscribed, 
pedunculated, exophytic growth with a granular or 
cauliflower-like surface. Histologically, the oral squamous 
papilloma consists of many long, thin finger-like 
projections of stratified squamous epithelium extending 
above the surface of the mucosa with overlying 
ortho/parakeratin, supported by a central fibrovascular 
connective tissue core, containing an inflammatory 
infiltrate. In 80% of the cases, it may have secondary and 
tertiary branchings that are covered by orthokeratin or 
parakeratin or both. The essential feature is a 
proliferation of the spinous cells in a papillary pattern. 
Mitotic activity is prevalent and variable levels of 
cellular atypia are present. Koilocytosis of the epithelial 
cells in the upper layers may be found which is thought to 
be indicative of viral infection. Koilocytes are cells where 
the cytoplasm have suffered vacuolation and as a consequence 
the nuclei appear as sorrounded by an halo or empty space. 
The human papillomavirus is an etiologic agent of ~he oral 
squamous papilloma, HPV types 2, 6, 11 and 16 have been 
related to these lesions. 
Differential diagnosis of the oral squamous papillomas 
should be made with oral condyloma acuminata and oral 
verruca vulgaris, since clinical and histological 
similarities exist, making it difficult to differentiate 
among them. 
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Clinically, the oral condyloma acuminatum is a 
painless, soft, sessile, sexually transmitted viral 
papillomatous lesion. The color is similar as or lighter 
than the surrounding tissue. Rare in the oral cavity, it is 
mostly seen in adults but also has been observed in children 
who have been sexually abused. The sex partner will have 
similar lesions in such case. 
Histologically, the oral condyloma acuminatum exhibits broad 
papillary folds with bulbous appearing rete ridges and 
parakeratin crypts. The stratified squamous epithelium is 
often parakeratinized but it may also be non-keratinized. 
The upper spinous cell layer shows koilocytotic changes, 
there is acanthosis and sometimes ballooning type of nuclear 
degeneration as seen in focal epithelial hyperplasia. 
Human papillomaviruses are the etiologic agents of condyloma 
acuminatum. HPV types 6, 11, and 16 have been associated 
with these lesions. 
Clinically, the oral verruca vulgaris is a painless, 
papillary lesion with white surface projections due to 
keratin production. It may be undistinguishable from 
papilloma. While common in skin of children and young 
adults, it is uncommon intraorally. When present in oral 
mucosa, the verruca vulgaris is mainly located on the palate 
followed by the alveolus, gingiva, tongue, commissures and 
buccal mucosa. They exhibit varied clinical presentations 
from focal exophytic lesions to multiple or spreading 
verrucous lesions. 
Histologically, the oral verruca vulgaris may present three 
different types of patterns: 
1. Acropapilloform, which consists of both angulated and 
rounded papillomatous projections and abrupt cupped 
margins. It is the most common pattern. 
2. Acroform, which consists of acutely angulated verrucous 
projections with discrete margins. It is the second 
common pattern. 
3. Cryptoform, which consists of bulbous acanthotic 
invaginations, cornified crypts and discrete margins. It 
is the least common of the variants. 
The majority of the oral verruca vulgaris cases, present 
both ortho and parakeratin. In some cases, koilocytes might 
be seen in the granular and upper spinous cell layer, where 
they can appear as small, vacuolated cells with pyknotic 
nuclei or as larger, pale cells with small dark nuclei. 
The human papillomaviruses are the etiologic agents of the 
oral verruca vulgaris. HPV types 2 and 4 have been 
associated with these lesions .14,1s,1s,11,1a,1s,20,21,22 
The methods used until now for the detection of HPV 
infection of cells are: 
1. Hematoxylin-eosin stain, used for the observation of 
histomorphologic changes present in tissues such as 
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koilocytes and other cellular/nuclear atypias. Performed 
on fixed tissues mounted on slides. Method not sensitive 
for the detection of HPV. 
2. Electron microscope, used for the observation of viral 
particles but viral particles must be assembled. 
Performed on fixed tissues mounted on slides. Method not 
as sensitive as melecular genetics. 
6 
3. Immunoperoxidase stain of HPV antigen, used for the 
observation of viral proteins. Performed on fixed tissues 
mounted on slides. Method not as sensitive as molecular 
genetics. 
4. Southern blotting, used for the observation of cleaved 
viral DNA subjected to electrophoresis, then hybridized. 
Requires fresh or fresh-frozen specimen; sensitivity of 
detection about 105-106 copies of the genome; labor 
intensive. Research tool, most reliable method for HPV 
typing. 
5. Dot blot hybridization, used to observe uncleaved 
denatured viral DNA blotted onto membranes, then 
hybridized. Requires fresh or frozen specimen; 
sensitivity of detection similar to Southern 
hybridization; difficult to discriminate weak signal 
from background. Research tool for screening of HPV 
types. 
6. DNA "in situ" hybridization, used to observe viral DNA 
localized to cells on sections using probes. Can be 
performed on fixed tissues; sensitivity of detection 
variable; labor intensive. Research tool, 
commercial kits available. 
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7. Polymerase chain reaction, is used to observe viral DNA 
fragments amplified, but not localized to specific cells. 
Performed on fresh or fresh-frozen specimens as well as 
in fixed specimens. Sensitivity of detection 10 to 100; 
potential for false-positive results because the test can 
pick up even low-level contamination. Research tool, the 
most sensitive technique, contamination problems, 
rapid.23,24 
The objectives of this investigation were: 
First, to detect HPV DNA in oral squamous papillomas by 
the use of "in situ" hybridization, which localizes specific 
nucleic acids, DNA or RNA, in this case DNA sequences, 
within the cells of tissue specimens. This was accomplished 
by using wide spectrum and type specific probes. The wide 
spectrum probe (WSP) targets genomic DNA of HPV types 6, 11, 
16, 18, 30, 31, 33, 35, 45, 51 and 52 but does not 
distinguish among them. The type specific probes (TSP) 
target genomic DNA of HPV types 6, 11, 16, 18, 31 and 33 
individually. 
The "in situ" hybridization method was selected for this 
investigation since it preserves the morphology of the 
tissue, thus allowing to associate abnormal morphology with 
HPV infection and to visualize the stratum in the epithelium 
where HPV DNA is located which is not possible with the 
other techniques mentioned above. 
Eleven of the HPV types targeted by the wide spectrum and 
specific probes have been implicated in different types of 
epithelial lesions: 
HPV type 6 have been detected in cervical 
intraepithelial neoplasia, genital warts (condyloma 
acuminatum), laryngeal papillomas, oral 
warts/papillomas, verrucous carcinoma (Buschke-
LOwenstein tumor), vulvar carcinoma. 
HPV type 11 in cervical epithelial neoplasia, genital 
warts, laryngeal papillomas, oral papillomas, penile 
carcinomas. 
HPV type 16 in cancers of the anogenital region, high-
grade intraepithelial lesions, lung carcinoma, oral 
carcinoma, oral hyperkeratotic lesions, oral mucosa. 
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HPV type 18 in carcinoma of cervix and penis, invasive 
carcinomas of the anogential region, macular lesions of 
epidermodysplasia verruciformis. 
HPV type 30 in laryngeal carcinomas. 
HPV type 31 in carcinoma of cervix and high-grade 
intraepithelial lesions of the anogenital region. 
HPV type 33 in Bowenoid papulosis, carcinoma of cervix, 
cervical intraepithelial neoplasias. 
HPV type 35 in carcinoma of cervix, cervical 
intraepithelial neoplasias. 
HPV type 45 in genital warts, invasive carcinoma of the 
cervix. 
HPV types 51 and 52 in high-grade intraepithelial 
lesions of the cervix. 25 
One hundred papilloma specimens were first assayed by 
the Avidin-Biotin-Peroxidase Complex for 
immunohistochemistry technique which detects HPV ant~gen. 
The papillomas that yielded positive results with the use of 
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antibodies to HPV proteins were assayed with the wide 
spectrum probe. And in turn, those specimens that yielded 
positive for HPV DNA with the Wide Spectrum Probe, were each 
in turn assayed with all the type specific probes 
individually. 
The inununohistochemistry technique was used as a method of 
selection of the papillomas to be tested with the Wide 
Spectrum Probe, although the absence of HPV antigen does not 
rule out the presence of HPV DNA. 26 
Second, to establish "a risk profile for malignancy", 
in order to determine which lesions have the potential for 
becoming malignant according to the type of HPV present. 
This profile would be based on the following criteria: 
1. "Low risk" lesions are those induced by HPV types 
6, 11, 42, 43 and 44. These types have very 
low potential for malignant transformation. 
2. "Intermediate risk" lesions are those induced by 
HPV types 31, 33, 35, 51, 52 and 58. These types 
might or not induce malignant transformation. 
3. "High risk" lesions are those induced by HPV types 
16, 18, 45 and 56. These types have a high 
potential for malignant transformation. 27 
Third, to establish the location of HPV DNA in the 
epithelium, since it is usually found in the nuclei of 
keratinocytes in the stratum granulosum and stratum 
corneum. 28 But, could it also be found in the basal fayer? 
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Fourth, to determine which HPV type is present in each 
papilloma specimen, due to the fact that each papilloma 
could be infected with more than one type of HPV DNA. 
Fifth, to compare histomorphologically the papillomas 
which express HPV DNA and those papillomas which do not 
express HPV DNA, based on the following criteria: 
1. Presence or absence of orthokeratin or parakeratin 
or both. Is the epithelium hyperkeratinized? 
2. Presence or absence of koilocytosis. 
3. Presence or absence of acanthosis. 
4. Presence or absence of cellular atypia. 
5. Presence or absence of basal cell layer replication. 
As a result, I expected to find features characteristic 
of viral infection such as: hyperkeratosis, koilocytosis, 
dyskeratosis, papillomatosis and acanthosis. 
And based on the findings of this investigation, a re-
definition of "oral squamous papillomas" was suggested. 
REVIEW OF RELATED LITERATURE 
Genus Papillomaviruses of the Papovaviridae family, are 
classified as such by virtue of their capsid structure and 
biochemical composition. They induce tumors in skin and 
mucosa and their name comes from the Latin, meaning papilla, 
nipple, pustule and the Greek suffix "oma", to denote 
tumor. 29 Each virus is named after its natural host in its 
English or Latin form. 
The "type" of papillomavirus is determined, based on the 
degree of DNA homologies. In case of less than 50% cross-
hybridization under stringent conditions, two isolates are 
considered as independent; if more than 50% cross-
hybridization, but incomplete, then they are considered sub-
types (ex. HPV type 6b [b=subtype]). 30 When tested under 
stringent conditions, the members of individual groups 
cross-hybridize from less than 1% to 40%. 31 • 32 HPV types 6 
and 11 which affect the mucosa, show 25% of cross 
hybridization and very similar biological properties. 33 • 34 
In general, the sequences of all papillomaviruses are highly 
homologous, specially within El and Ll, which leads to 
cross-hybridization between their DNAs under conditions of 
reduced stringency. 35 
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The human papillomaviruses (HPV) are small, non-
enveloped, composed of icosahedral particles which contain 
DNA and protein. The DNA is composed of 8000 base pairs, 
circular, double-stranded, encapsulated in an outer protein 
shell of 72 capsomeres, in a skew structure either left-
handed (cotton tail rabbit papillomavirus), or right-handed 
(human papillomavirus). 36 After negative staining, the 
capsomeres appear as hollow cylinders of equal height and 
width, which are connected at their base by fibrous bridge-
like structures. 37 All the genetic information is localized 
on one strand. The viral genome is divided into: 
a. An early region (about 4.5 kilobases [KB]), which 
contains eight reading frames El-ES, which are necessary 
for viral replication and transformation. 
b. A late region (about 2.5 KB), composed of two Ll and L2 
open reading frames, which are the potential coding 
regions. 
c. A regulatory or long control region (LRC), (about 1 KB), 
which contains the origin of replication and the control 
elements for the transcription and replication. 38 
The E6 and E7 are the transforming proteins. The E7 proteins 
bind to the retinoblastoma tumor suppressor gene product 
(pRB), with a preference for the underphosphorylated 
"active" form of pRB. The E7 proteins derived from the "high 
risk" HPVs bind to pRB with a higher affinity than the E7 
proteins from the "low risk" HPVs. The "high risk " HPV E6 
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proteins can associate with the tumor suppressor p53 in 
vitro and enhance their degradation, which presumably 
accounts for the very low levels of p53 in cervical 
carcinoma cell lines. The expression of E6 protein 
substitutes for mutations within the p53 gene and seems to 
lead to loss of functional p53. While, HPV negative 
anogenital cancers show evidence of clonal somatic mutation 
within p53. Suggesting that expression of a mutant p53 
protein contributes to the development of HPV negative 
tumors, which results in the expression of an altered p53 
protein that may gain positive transforming activity, in 
addition to losing wild type function. Therefore, HPV 
negative cancers, are more aggressive in nature than HPV 
positive cancers since they express a mutant p53. 39 • 40 
The virus enters the mucosa through a loss of 
continuity in the epithelium, where it infects the basal 
layer. Here, the virus causes transformation of basal cells, 
but do not undergo lytic replication, since basal cells are 
non-permissive to viral replication. As keratinization takes 
place, cells become permissive to viral replication. 
Keratinocyte differentiation then, results in viral DNA 
replication, synthesis of structural proteins and induction 
of virus-specific cytopathic effects. In humans the 
incubation period varies between 3 and 18 months. As 
epithelium differentiates, there is early (non-structural) 
protein synthesis and episomal DNA replication, which will 
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either produce a condyloma or low grade epithelial lesion or 
latent infection or integration of viral DNA into host 
cellular genome (HPV types 16, 18, 31). Integration causes 
inactivation of tumor suppressor genes of host cells which 
accompanied by co-factors, could result in malignant 
transformation. The above takes place with comcomitant 
productive DNA synthesis and late (capsid) protein synthesis 
with assembly of viral particles. As desquamation of 
epithelium occur, cells are shed off into the environment, 
which results in re-infection and transmission of the 
virus. 41 • 42 But, progression of a benign papilloma to a 
malignant carcinoma, is accompanied by cessation of 
productive viral replication and alteration of the pattern 
of keratinization. 43 
HPV is transmitted through transplacental transmission, 
contamination during passage of fetus through bir~h canal, 
contact with an infected person, autoinoculation as in the 
case of thumb-sucking habits, 44 sex or fomi tes. 45 
Reports of congenital condyloma acuminatum, 46 juvenile 
laryngeal papillomatosis, 47 presence of HPV DNA in the oral 
cavity, foreskin48 and amniotic fluid of newborn babies, 49 
and the presence of HPV DNA in both cord and venous blood of 
newborns babies born to mothers with HPV DNA in peripheral 
blood mononuclear cells, suggest transplacental transmission 
of the virus. 50 Newborns acquired laryngeal papillomas from 
genital HPV infection by one of three ways: By direct 
contact, between the fetal larynx and the infected genital 
tract of the mother, by transplacental transmission, or by 
post-natal contact. 51 
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Sexual transmission results from ore-genital sex or contact 
with infected partner through an abrasion in the 
mucosa. 52 •53 HPV type 16 DNA, has been detected in the 
semen from male partners of women with HPV infection by the 
polymerase chain reaction. The male harbored same HPV type 
as the women. 54 
There exists an immune response in organisms infected 
by HPV, which is most evident in cases of immunosupression 
which predisposes the individual to HPV infection, 55 and in 
regressing warts. 56 Antibodies to E7 protein are found in 
sera of about half the cases of invasive cervical carcinomas 
associated with HPV-16 but less frequently in control sera 
or in sera of carcinoma cases not associated with HPV-16. 57 
In the treatment of HPV-induced lesions, surgical 
removal is the most frequent method used. Interferons which 
have general antiviral, antiproliferative and 
immunomodulating effects, are also being used. In one study, 
1/3 of refractory genital condylomas disappeared and an 
additional 1/3 of the condylomas decreased in size but 
interferons have been less effective in the treatment of 
respiratory papillomas. 58 •59 Autogenous vaccines have been 
effective with variable success. It is thought that 
immunization with capsid proteins (Ll and L2), may prevent 
16 
infection and that immunization with transforming proteins 
(E6 and E7) may prevent progression to malignancy or reduce 
tumor load in established cancers. The best prevention of 
HPV infection, is the avoidance of high risk behavior. 60 
According to the literature review between the years of 
1965 to 1992, the following studies of different lesions of 
the oral cavity have been conducted in order to detect the 
presence of HPV in different oral lesions: 
1. oral hairy leukoplakia was studied in thirty two patients 
infected with human immunodeficiency virus (HIV), with light 
microscope. Ultrastructural studies were conducted in 20 of 
the cases, where viral particles of the human herpes virus 
were detected in 17 of the cases and no HPV viral particles 
were found. Immunohistochemical studies were made in 26 
cases using a rabbit antiserum to papillomavirus where 
nuclear positivity was observed in 25 of cases. 61 
2. Eighty-eight formalin-fixed, paraffin-embedded invasive 
squamous carcinomas were studied for HPV types 16 and 18-
related DNA sequences following in vitro gene amplication 
using the polymerase chain reaction (PCR). Nine of the 25 
(36%), oropharyngeal squamous carcinomas contained HPV DNA 
sequences, including 4 of 10 (40%) laryngeal, 3 of 8 (38%) 
buccal and 2 of 7 (29%) glossal tumors. Of the 44 cases that 
contained viral DNA, HPV type 16 was detected in 41 cases 
(93%) and HPV type 18 in 5 cases (11%), while both types 
were found in 2 cases, (one anal and one vulvar). 62 
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3. One hundred and fifty six formalin-fixed, paraffin-
embedded biopsies from 40 patients with surgically treated 
oral squamous carcinoma were analyzed for the presence of 
HPV infection by histopathologic evaluation, DNA "in situ" 
hybridization and PCR. Morphologic changes suggesting 
infection by HPV were found in 16 out of the 40 patients 
(40%), HPV DNA was demonstrated in one of the lesions by "in 
situ" hybridization, with a biotin-labelled probe, for types 
6, 11, 16 and 18, and with the PCR technique, samples from 
11 of the 40 patients proved to contained HPV DNA. Of these, 
HPV- 6 was demonstrated in one case, HPV-16 in 9 cases, and 
HPV-18 in one case. HPV DNA was exclusively detected in the 
biopsies showing carcinoma tissue or its adjacent precancer 
lesions. 63 
4. A total of 206 benign oral mucosa! biopsy specimens were 
studied by the indirect immunoperoxidase (IP-PAP) technique 
to detect HPV antigens. Forty five of the 92 oral squamous 
papillomas/condylomas studied were positive for the HPV 
antigen. Also, 144 surgically treated benign oral lesions 
(which were included in the 206 lesions listed above), were 
analyzed using an DNA "in situ" hybridization technique with 
a 35S-labeled HPV (radioactive), to demonstrate HPV types 6, 
11, 13, and 16, in routinely processed, paraffin-embedded 
biopsy specimens. HPV DNA was present in 45 of the 144 
lesions, being found in 33.8% of the papilloma/condyloma 
group. Fifteen of these 45 lesions also expressed HPV 
antigens. The most frequent HPV type was HPV-11, 
representing 37.8% of the DNA positive lesions. HPV-16 DNA 
was found in 4 of the papilloma/condyloma lesions, (from a 
total of 92).~ 
s. A 33-year-old immunosuppressed man, developed bowenoid 
papulosis on his genitalia, velvety papules and plaques in 
his mouth and invasive squamous cell carcinoma of his 
tongue. All three lesions tested positive for HPV type 
16.~ 
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6. DNA biotinylated probes for HPV types 6, 11, 16, and 18 
were tested in cytostin preparations of fine-needle 
aspirates obtained from 5 squamous cell carcinomas of the 
head and neck (four metastatic in lymph nodes and one 
primary). All five carcinomas showed reactivity with probe 
11, four were strongly reactive, and one also reacted weakly 
with probe 16. HPV types 6 and 18 showed no reactivity. 66 
7. Ten specimens from 5 patients diagnosed as fibropapilloma 
were analyzed with the electron microscope. Specimens were 
taken from the proliferative lesion and from the normal 
sorrounding mucosa. HPV viral particles were seen in the 
non-keratinized epithelial cells as spherical particles 40-
55 nm in diameter, mostly in the cytoplasmic matrix and 
nuclei (especially on their chromatin masses), of the 
intermediate and superficial layers, which did not form a 
crystal array. Some viral particles were distributed in the 
extracellular spaces of the intermediate layer, and they 
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were hardly observed in cells of the basal/suprabasal and 
prickle layers. All the membranous organelles of the 
epithelial cells were devoid of viral particles. There were 
no significant differences in the HPV distribution between 
the cells derived from the proliferative lesions and those 
derived from the surrounding normal mucosa. 67 
8. Two hundred and seventeen tissue samples from various 
human malignancies were examined for the presence of HPV DNA 
with a low-stringency filter hybrydization technique, these 
techniques were sensitive enough to crosshybridized with all 
known papillomavirus DNAs, both animal and human. 
Approximately, 2% of the cancers contained HPV DNA, these 
included carcinomas of the lung, coecum, tongue and neck. 
Thirteen of 4 cancers, contained HPV-16-related nucleotide 
sequences. 68 
9. Eighteen salivary gland pleomorphic adenomas, including 9 
with a t(3;8) (p2l;q12) as the sole chromosome abnormality, 
were tested for the presence of HPV DNA and for 
rearrangements of the cellular flanking regions of a HPV-16 
integration site maping to 3p21. None of the tumors 
expressed HPV DNA or related sequences or rearranged allele 
of the integration site. 69 
10. Thirty-three cases of hairy leukoplakia in HIV-positive 
\ 
patients were examined. Twelve out of 14 cases studied under 
the electron microscope showed only herpes viral particles 
but 95% of the 33 cases were positive for HPV antigen when 
20 
studied by immunohistochemistry. 70 
11. In sections of 373 formalin-fixed, paraffin-embedded 
samples from benign and precancerous leukoplakias and 
squamous cell carcinomas, HPV DNA was identified in 56 of 
the specimens by the "in situ" hybridization technique. 71 
12. Seven biopsies from carcinomas of the tongue were 
analyzed for the presence of HPV sequences by Southern blot 
analysis. One tumor was positive with HPV type 2 under 
conditions of high stringency and two were positive for HPV 
type 16. All tumors contained high copy numbers of their 
respective viral DNA. The cleavage pattern of the HPV-2 
positive cancer differed from the established HPV-2 
prototype and one of the HPV-16 positive cancer also 
differed from its prototype. 72 
13. Biopsies from 40 cases of oral squamous cell carcinomas 
were examined with light microscope to look for features of 
HPV infection and by immunoperoxidase to detect the presence 
of HPV antigen. Morphological signs of the flat-type HPV 
lesion were found in 4 cases (10%), of the inverted type in 
3 cases (7.5%), and of the papillomatous type in 9 cases 
(22.5%). Koilocytosis was seen in most of the antigen 
positive lesions, 5 of which were of the papillomatous type, 
2 of the inverted type and 1 of the flat type. 73 
14. Forty-five oral papillary lesions classified clinically 
and histologically as condylomatous papilloma, 
hyperkeratotic papilloma and oral wart were subjected to 
21 
histopathological evaluation and tested by immunoperoxidase 
for HPV group-specific antigens. HPV antigen was found in 
10% of 31 condylomatous papillomas, 22% of the 9 
hyperkeratotic papillomas, and 60% of 5 oral warts. 
Koilocytosis of varying extend was regularly observed and 
quantified. 74 
15. HPV types 4, 16 and 18 were detected in biopsies of 
normal and malignant human mucosa by Southern blot 
hybridization and polymerase chain reaction (PCR). HPV DNA 
from types 4, 16, 18 were detected in three different 
carcinomas but viral DNA was only found in adjacent 
dysplastic and normal tissue with PCR. The HPV-18 DNA 
detected by Southern blot hybridization showed an altered 
restriction pattern in region El of the viral genome; 
however direct nucleotide sequencing of PCR products from 
the E6 open reading frame showed no sequence alterations in 
either normal or malignant samples. 75 
16. Five papillomas, five leukoplakias and six carcinomas 
were investigated for the presence of papilloma group-
speci f ic antigens, with genus-specific papillomavirus 
antibodies and viral DNA, with cloned HPV types 11 and 16 
DNA, used as probes in Southern blot hybridization at 
conditions of different stringency. Four of five papillomas, 
four of five leukoplakias and three of six carcinomas 
reacted with HPV DNA probes and revealed some stained cells 
after exposure to HPV antibodies. HPV-16 was found in one 
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carcinoma and HPV-11 in another case of carcinoma. 76 
17. Lesions of the oral mucosa, from 10 patients suffering 
from focal epithelial hyperplasia (FEH), were studied for 
the detection of HPV DNA by blot hybridization technique. 
Four of the patients showed HPV type 13 DNA while the other 
six patients showed a new HPV type, tentatively named HPV-
32. Also, oral papillomas from 14 additional patients were 
analyzed, 5 of which expressed HPV DNA: HPV-6 was detected 
in a condyloma and a papilloma, 2 showed uncharacterized HPV 
DNAs and one showed HPV-32, the latter showing histologic 
characteristics of FEH. Thus, FEH was conceived as a disease 
associated with HPV types 13 and 32. 77 
18. Twenty formalin-fixed, paraffin-embedded specimens of 
human immunodeficiency virus (HIV) positive patients, were 
evaluated for the presence of HPV genus-specific antigen, 
HPV- 2/4, 6/11 and 16/18 DNA and Epstein-Barr virus (EBV), 
by "in situ" hybridization. Three cases exhibited HPV 
antigen in the cytopathologically altered spinous layer 
keratinocytes and only one exhibited HPV types 16, 18 or 
related sequences. While, 19 cases were found to harbor EBV 
DNA, in the upper spinous layer koilocytes. 78 
19. Seventeen oral epidermoid carcinomas, 3 oral papillomas 
and 17 normal gingival tissues were tested for the presence 
of HPV types 6, 11, 16 and 18 sequences, by Southern blot 
hybridization. In 76.4% of the oral carcinomas and in all 
the papillomas, HPV type 16 episomal sequences were 
23 
detected. None of the samples contained HPV types 6, 11, or 
18 sequences. Examination of the habits, showed that 59% of 
the patients were quid chewers and 82% were smokers. 79 
20. Seventy-seven tissue samples from patients with either 
degree I, II, or III smokeless tobacco keratoses were 
examined for the presence of HPV antigen by 
immunocytochemistry. The antigen was found in sixteen 
(20. 78%) cases. 80 
21. "In situ" hybridization, was used to detect HPV DNA 
types. Of 100 cases of benign leukoplakias, 4% of non-
tobacco-related and 10% of smokeless tobacco-related lesions 
harbored viral sequences. Of the dysplastic lesions, 3%, 
alternatively, 17% and 20% of the verrucous hyplerplasia and 
verrucous carcinomas harbored HPV. 81 
22. Twenty two cases of oral precancerous lesions (OPL) and 
51 cases of squamous cell carcinomas (SCC), routinely 
processed, paraffin-embedded biopsies were screened for the 
presence of HPV DNA, with a 35S-labelled probe containing 
types 6, 11, 13, 16, 18 and 30, by "in situ" hybridization. 
The lesions which expressed HPV DNA were further analyzed 
with the six HPV DNA probes, separately. HPV-6 was found in 
one case of mild dysplasia, HPV-11 in 2 cases of mild 
dysplasia, HPV-16 in 2 dysplasias and in 3 carcinomas and 
HPV-18 in 1 moderate dysplasia and in 3 carcinomas. HPV 
types 16 and 18 were simultaneously present in one case of 
carcinoma. HPV-13 and 30 was not detected in any of the 
24 
lesions. 82 
23. Oral warts from 17 HIV-seropositive individuals were 
analyzed by Southern blot. HPV-7 was found in 7 warts, HPV-
13 in 1, HPV-32 in 1 and HPV-18 in 1 from a total of 17 oral 
warts. There was no correlation between HPV type, 
histopathology and clinical apperance of the lesions 
studied, except that the flat warts (FEH types), contained 
HPV types 13, 18 and 32 (one of each). 83 
24. One hundred and forty oral squamous cell papillomas 
(SCPs) were subjected to immunoperoxidase-PAP method to 
detect HPV antigen. Positive intranuclear staining was seen 
in 41% of the cases, 9% showed both intranuclear and 
cytoplasmic staining and 50% were negative for the 
antigen. 84 
25. Four oral papillomas and 7 carcinomas were studied by 
"in situ" hybridization, with a HPV 16 biotinylated probe 
under different stringent conditions. Subsequently, a 
modified biotin-avidin-alkaline phosphatase procedure was 
used to visualize virus-infected cells. Four papillomas and 
4 carcinomas were found to contain HPV DNA. Positive cells 
were located in superficial and intermediate cell layers in 
papillomas and in keratinized zones in carcinomas. 85 
26. Seventeen tissue specimens from 9 patients with oral 
verrucous cancer were obtained, pre-malignant lesions and 
primary and recurrent tumors were included. Samples were 
tested for the presence of HPV DNA, by "in situ" 
25 
hybridization with biotin-labelled probes. Under conditions 
of low stringency (Tm-35 degrees), one pre-malignant lesion 
and lesions from 2 other patients, hybridized with 3 
different probes. The pre-malignant lesion also was positive 
for HPV structural antigen. Under conditions of high 
stringency, the lesions were each positive for HPV type 
2. 86 
27. Sixty-two oral condyloma acuminatum were tested. HPV 
antigen was detected in 25% of the cases in the upper 
spinous layer by a immunocytochemistry method, while 85% of 
the cases expressed HPV types 6, 11 or related genomes, by 
"in situ" hybridization under conditions of high stringency. 
One case was found to harbor HPV type 2. 87 
28. Eleven oral verruca vulgaris were examined for the 
presence of HPV antigen by reaction with antibody to type 
common antigens and detection by the Avidin-Biotin-
Peroxidase Complex method. The specimens were also examined 
by "in situ" hybridization with biotin-labelled specific HPV 
type probes. Six of the 11 specimens were positive for HPV 
antigen and of these 6, five hybridized to the HPV-2 probe 
and one to the HPV-4 probe. 88 
29. Erosive oral lichen planus (OLPe) lesions from 20 
patients were examined with 32P-labeled HPV DNA probes by 
Southern blot hybridization. HPV type 11 was detected in 6 
of the lesions while HPV types 6, 16 and 18 were not 
detected in any of them. Also, a type-specific polymerase 
chain (PCR), reaction assay was used. With the PCR method, 
HPV type 11 was detected in 8 of the samples, HPV-6 in 5 
samples and HPV-16 in 3 samples. 89 
26 
30. DNA extracted from a odontogenic keratocyst was assayed 
for the presence of HPV type 16 using Sou_thern blot 
hybridization. The HPV type 16 DNA sequences detected were 
different from the prototype HPV-16. 90 
31. Eighteen cases of focal epithelial hyperplasia (FEH), 
were investigated for the presence of HPV antigen by 
immunohistochemistry and to detect the presence of HPV types 
1, 6, 11, 13, 16, 18 and 32 DNA, by "in situ" hybridization 
employing biotinylated probes. Seven of the cases (39%), 
expresed HPV group specific antigen while 15 cases (83%), 
expressed HPV DNA. Nine cases (60 %), expressed HPV-32, five 
cases (33%), expressed HPV-13 and one case (7%) expressed 
HPV-11. Two specimens on different sites from the same 
patient expressed the same type of virus and one patient 
had, in addition to FEH, a squamous papilloma demonstrating 
the same type of virus. 91 
32. Two oral lesions, one from the lower lip, the other from 
the buccal mucosa, from a 30-year-old HIV-positive and 
immunosuppressed man, were examined by Southern blot 
hybridization. Under low stringency, both lesions hybridized 
with a probe coktail comprising HPV types 6, 11, 16, 18, 31 
and 33 DNA. Under high stringency, the lip lesion, proved 
to contain HPV-7, which also was confirmed by "in situ" 
27 
hybridization. The buccal lesion was weakly positive with 
types 11 and 13, but the restriction patterns with Pst I and 
Bam HI did not fit with the HPVs known so far. Cloning of 
this new type of HPV is under way. 92 
33. Seventeen cases of focal epithelial hyperpasia (FEH) 
were investigated by the use of "in situ" hybridization 
using biotinylated probes of HPV types 1, 6, 11, 13, 16, 18 
and 32 DNA. Ten cases were positive for HPV type 13 and 6 
cases were positive for type 32 DNA. One case showed doubled 
infection with types 13 and 32 DNA. 93 
34. Five focal epithelial hyperplasia (FEH) specimens from 4 
patients were evaluated for the presence of HPV DNA by 
Southern blot hybridization. FEH lesions from 3 patients 
that shared a familial relationship demonstrated HPV-13 DNA 
sequences or a closely related sub-type and similar clinical 
features. The other patient harbored sequences very similar 
to HPV-32. 94 
35. Biopsies from 9 oral papillomatous lesions were analyzed 
by Southern blot analysis with 32p-labelled cellular DNA, to 
detect HPV types 1 to 19 and 21 to 26 DNA sequences. Of the 
three cases diagnosed as focal epithelial hyperplasia, 2 
contained HPV-6 related sequences and one HPV-11. One tongue 
base papilloma and one papilloma of the palate, contained 
HPV-11. Of the remainding lesions, 2 contained HPV-6. 95 
36. Twenty-one papillomas, 23 ordinary benign keratoses. 13 
smokeless tobacco keratoses, 10 verrucous hyperplasias, 10 
28 
verrucous carcinomas, 17 squamous cell carcinomas, 3 
epithelial dysplasias and 6 lichen planus, were evaluated 
for HPV types 6/11, 16/18, 31/33/35, with biotinylated 
doubled-stranded DNA probes. Sixty-two per cent (13/21), of 
the papillomas were positive for HPV DNA, being the 
strongest reactivity for types 6/11. Of the 13 cases, 10 
also showed some reactivity with types 16/18 and 31/33/35. 
None of the other lesions showed HPV DNA. 96 
37. Twenty representative papillomas were evaluated for the 
presence of papilloma genus-specific antigen by 
immunoperoxidase technique and for HPV types 2, 4, 6 and 11 
by "in situ" hybridization, with biotinylated full-length, 
doubled-stranded DNA probes. Only one case exhibited antigen 
reactivity. Seven cases (35%), yielded positive for HPV-6 or 
11 and one exhibited a dual infection with HPV types 2 and 
6. 97 
38. Forty nine cases of primary verrucous or squamous cell 
carcinoma were examined by Southern blot hybridization to 
detect HPV types 2, 6, 11, 13, 16, 18, and 32. 
Approximately, 60% of carcinomas particularly of the mouth, 
tongue, pharynx, piriform sinus and larynx, were positive 
for episomal viral DNA of HPV types 6, 11, 16 or 18. The 
remainding 30 carcinomas, were examined by polymerase chain 
reaction amplification assay, for DNA of HPV types 6, 11, 16 
and 18, twenty-seven of which were positive for types 16 or 
18 DNAs. 98 
29 
39. The sensitivity of detection of HPV DNA in pre-malignant 
and malignant oral lesions between "in situ" hybridization 
(ISH) and polymerase chain reaction (PCR), was compared. 
With both methods, HPV DNA was found in 4 of 24 cases of 
epithelial dysplasia, 4 of 14 cases of verrucous hyperplasia 
and 1 of 10 cases of squamous cell carcinoma. The 10 cases 
of smokeless tobacco keratoses and 3 cases of verrucous 
carcinoma studied were all negative for HPV DNA. Only a 
single case that was positive by PCR was negative by ISH. 
Also, the PCR demonstrated the presence of HPV-16 infection 
in one case, which hybridized most intensively with the 
probes for types 31/33/35 in the ISH. 99 
40. Thirty-two surgically treated, paraffin oral lesions 
were tested by "in situ" hybridization to detect HPV types 
6, 11 and 16. A total of 10 lesions express HPV antigen, 
which were found in 4 of 7 squamous cell papillomas, in 2 of 
2 classic condylomas, in 2 of 10 papillary hyperplasias and 
in 2 of 3 leukoplakia lesions. Two of the squamous cell 
papillomas contained HPV 6 DNA and 4 contained HPV 11 DNA. 
One of the condyloma contained both, type 6 and 11 DNA 
while the other contained only type 11 DNA alone. Both the 
antigen-positive papillary hyperplasias and leukoplakias 
contained type 6 DNA. HPV type 16 was found in one lichen 
pl anus and one of the 2 squamous cell carcinomas. 100 
41. Fifty radomly selected oral squamous papillomas were 
tested with the peroxidase-antiperoxidase technique to 
detect HPV antigens. HPV-type 1 antigen was found in 2 of 
the papillomas. 101 
42. One hundred and five oral lesions were analyzed by "in 
situ" hybridization with biotinylated DNA probes for HPV 
types 6 and 11; 16 and 18; 31, 33 and 35. Positive 
hybridization signals were found in 26 specimens and only 
HPV types 6/11 was detected (24.8%). HPV DNA occurred in 
100% of the condyloma acuminatum and verruca vulgaris, in 
13.3% of the squamous papillomas, 10% of 
hyperkeratotic/acanthotic lesions and 0% of malignant and 
pre-malignant lesions. The tongue (19.1%) and the labial 
epithelium (17.1%) were infected most frequently. Nuclear 
staining was seen mostly in koilocytes. 102 
30 
43. Samples from oral, sinus, pharynx and larynx lesions 
were tested under less stringent (25% formamide, 42 degrees 
C) and stringent (50% formamide, 42 degrees C) conditions. 
Three samples (laryngeal papillomas) from 10 benign tumors 
and 3 of 30 malignant tumors, contained HPV-related 
sequences. The 3 laryngeal papillomas contained HPV types 
11, 6 and 11 or 6, respectively. In the malignant tumors, 
neither the typical restriction pattern of HPV DNA or viral 
antigen was detected, suggesting that subgenomic fragments 
remained integrated in the host cell. 103 
44. A series of 191 oral mucosal tumors were analyzed by 
indirect immunoperoxidase IP-PAP technique for the presence 
of HPV structural proteins, of epithelial dysplasia and for 
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cellular composition (B and T lymphocytes, mononuclear 
phagocytes,[MPS cell]), of their local inflamatory cell 
infiltrates using ANAE (acid alpha-naphthyl acetate 
esterase). HPV structural proteins were disclosed in 85% of 
focal epithelial hyperplasia (FEH), 75% of condyloma 
acuminatum (CA) and 41% of squamous cell papillomas (SQP). 
Mild dysplasia was found in 20% of both CA and SQP and 
moderate dysplasia was found in 12% of the CA. B cell 
infiltrate was also more predominant in cases of CA and 
SQP.104 
45. One hundred one patients, 66 female and 35 male, with 
genital condylomata underwent an oral cavity examination. 
Ninety-nine (99%) practice oral sex and 91 out of these 
underwent oral biopsies with a diagnosis of condyloma in 48% 
of 101 specimens collected. Of these 8 of 91 (9%) oral 
lesions were suspected by naked-eye and on colposcopic 
examination, 83 of 91 patients were suspected of having oral 
condyloma. Of these 83 patients, 38 (46%) were confirmed 
histologically, thus a total of 46 patients with genital 
condyloma also exhibited oral condyloma and 38 of these 46 
patients had condylomas not visible clinically. Twenty 
cytological oral samples were also collected for DNA filter 
"in situ" hybridization analysis. HPV DNA genital types were 
observed in 45% (9/20) of all oral scrapings studied and all 
were confirmed histologically •105 
46. Twenty-five oral hairy leukoplakia (OHL) lesions from 35 
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HIV-infected patients stained with antibody to 
papillomavirus common structural antigens. HPV DNA was 
detected in 10 of 18 OHL specimens and in 6 of 10 normal 
buccal mucosa specimens. Epstein-Barr virus (EBV) was also 
being tested in this study. The results indicate that HPV 
can be found regularly in histologically normal mucosa . 106 
47. A white spongeous nevus was assayed by Southern blot 
hybridization for the presence of DNA sequences homologous 
of HPV types 1, 2, 4, 6, 11, 13, 16 and 18. Only HPV-16 
homologous DNA sequences were detected at a copy number of 
approximately 200 to 250 genome copies per diploid cell. The 
viral DNA sequences did not appear to be integrated into the 
host cell chromosome. 107 
48. Lesions from twelve patients with recurrent respiratory 
papillomatosis were analyzed for the presence of HPV DNA, by 
the ViraPap/ViraType hybridization procedure. Biopsies were 
obtained from the respiratory papillomas and nondiseased 
sites (NOS) of the respiratory tract. Fifty percent of the 
patients with papilloma specimens typed positive (6 of 12) 
and 40% of the patients typed positive in one or more 
biopsies from the NOS (4 of 10). No oncogenic HPV types 
16/18 or 31/33/35 were detected and only patients with 
multiple, not isolated, papilloma involvement were found to 
harbor HPV DNA in NOS. Eighty percent of patients with HPV 
infected NOS, required a shorter (no more than 3 months) 
treatment interval, compared to 20% of those without HPV 
infected NOS. These results showed that HPV infection 
frequently persists in adjacent, clinically normal sites, 
and suggested that the extend of NDS involment may predict 
both the extent of disease and the likelihood of 
recurrence. 108 
49. Sixteen paraffin-embeded biopsy specimens of 
nasopharyngeal carcinoma (eight anaplastic and eight well 
differentiated squamous types), were examined for the 
presence of HPV types 16 and 18 by polymerase chain 
reaction. HPV DNA was not detected in any of the 
specimens. 109 
33 
so. A peripheral ameloblastoma was studied by "in situ" 
hybridization. Results were positive for HPV types 16/18 but 
negative for types 6/11 DNA. 110 
51. Twenty-four cases of tongue squamous-cell carcinoma 
(SCC) were analyzed by dot-blot hybridization technique and 
polymerase chain reaction method. HPV DNA were detected in 8 
cases. One poorly differentiated grade III specimens 
contained both HPV types 16 and 18; seven other cases 
contained HPV-16 DNA. 111 
52. Sixty formalin-fixed, paraffin-embedded carcinomas 
arising from the nasal cavities (NC) and paranasal sinuses 
were analyzed by using polymerase chain reaction. In cases 
of squamous cell carcinoma (SCC), (n=49), the authors also 
compared the clinical features of patients with HPV-positive 
and HPV-negative results, to determine the clinical 
significance of HPV in sec. HPV types 16 and 18 DNA were 
detected in 7 of the 49 cases (14%) of sec. In the other 
histologic types of carcinomas (n=ll), neither type was 
detected. No significant differences in the clinical 
features were observed between the HPV-positive and HPV-
negative scc. 112 
34 
53. Eight sinonasal carcinomas (one adeno carcinoma, two 
undifferentiated nasopharyngeal carcinomas and five squamous 
cell carcinomas) were investigated by "in situ" 
hybridization and polymerase chain reaction (PCR), for HPV 
types 6, 11, 16, 18 and 33. All eight cases were negative by 
"in situ" hybridization, while one case was positive for HPV 
type 6 by PCR. The HPV DNA positive case was an invasive 
papillary squamous cell carcinoma of the maxillary 
sinus. 113 
54. Forty benign histologically suspicious of HPV infection 
were analyzed with ViraType (Life Technologies, Inc. [LT]) 
and Pathogene (Enzo Diagnostics, Inc. [ED]), "in situ" 
hybridization kits for HPV DNA detection in oral tissue. The 
purpose of this study was to compare the sensitivity of both 
kits. Specimens were hybridized with DNA probes specific for 
HPV types 6/11, 16/18 and 31/33/35 [LT], and HPV types 6/11, 
16/18 and 31/33/51 [ED]. Positive hybridization reactions 
were seen for HPV DNA type 6/11 only and more often in the 
LT (20/40; ED=12/40), probed specimens. HPV DNA sequences 
were seen in 100% condyloma acuminata (13/13), 100% verruca 
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vulgaris (4/4) and 13% of the squamous papilloma, with the 
LT system. The ED system, yielded positive signals in 77% of 
condyloma acuminata (10/13), 25% verruca vulgaris (1/4) and 
4.4% squamous papillomas (1/23). 114 
ss. A case of verruca vulgaris in the larynx of a 37-year-
old woman was analyzed using the inunnunohistochemistry 
method, "in situ" hybridization and electron microscope. 
Papillomavirus capsid antigen, HPV types 6 and 11 DNA and 
viral particles were detected. 115 
HISTOMORPHOLOGICAL DESCRIPTION OF HPV 
WIDESPECTRUM POSITIVE AND NEGATIVE PAPILLOMAS 
CASE NO. 1277-92: Parakeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections with 
replication of the basal cell layer and supported by a 
fibrous stroma. Koilocytes are present in the stratum 
granulosum. BPV-1 positive, WS negative. 
CASE NO. 1227-92: Parakeratotic, acanthotic stratified 
squamous epithelial ridges disposed in papillary projections 
with replication of the basal cell layer which exhibits 
hyperchromatic nuclei and mitotic figures and supported by a 
fibrovascular stroma. Few koilocytes are present in the 
stratum granulosum. BPV-1 positive, WS positive. 
CASE NO. 1093-92: Orthokeratotic, acanthotic stratified 
squamous epithelial ridges disposed in papillary projections 
with replication of the basal cell layer and supported by a 
perivascular stroma. BPV-1 positive, WS negative. 
CASE NO. 1090-92: Parakeratotic, acanthotic stratified 
squamous epithelial ridges disposed in papillary folds with 
replication of the basal cell layer and supported by a 
fibrovascular stroma. Koilocytes are present in the stratum 




CASE NO. 717-92: Hyperparakeratotic, acanthotic stratified 
squamous epithelial ridges which curve centrally, exhibits a 
granular layer and is supported by a fibrous stroma. 
Koilocytes are present in stratum spinosum. BPV-1 positive, 
WS negative. 
CASE NO. 567-92: Orthokeratotic, stratified squamous 
epithelium disposed in papillary projections with basal and 
suprabasal cell layer mitotic activity and supported by a 
fibrovascular stroma. Koilocytes are present in stratum 
granulosum and upper stratum spinosum. BPV-1 positive, WS 
negative. 
CASE NO. 564-92: Parakeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections with 
replication of the basal cell layer, supported by a fibrous 
stroma. Koilocytes are present in stratum granulosum. BPV-1 
positive, WS positive. 
CASE NO. 492-92: Parakeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections, basal 
cell layer replication with mitotic activity in suprabasal 
and basal cell layers, supported by a fibrovascular stroma. 
BPV-1 positive, WS positive. 
CASE NO: 461-92: Orthokeratotic, acanthotic stratified 
squamous epithelial ridges disposed in papillary projections 
with replication of the basal cell layer and supported by a 
fibrous stroma. Koilocytes are present in the upper stratum 
granulosum. BPV-1 positive, WS negative. 
CASE NO. 236-92: Parakeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections with 
replication of the basal cell layer and supported by a 
fibrovascular stroma. Koilocytes are present in stratum 
granulosum and stratum spinosum. BPV-1 positive, WS 
positive. 
CASE NO. 214-92: Parakeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections with 
replication of the basal cell layer and a f ibrovascular 
supporting stroma. BPV-1 positive, WS positive. 
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CASE NO. 1065-90: Hyperparakeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections with 
replication of the basal cell layer and supported by 
hyalinized fibrous vascular cores of stroma. Koilocytes are 
present in stratum granulosum. BPV-1 positive, WS negative. 
CASE NO. 799-90: Hyperparakeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections with 
replication of the basal cell layer and a fibrovascular 
supporting stroma. Koilocytes are present in stratum 
granulosum and spinosum. BPV-1 positive, WS positive. 
CASE NO. 670-90: Hyperparakeratotic, acanthotic stratified 
squamous epithelial ridges disposed in papillary projections 
with mitotic activity and replication of the basal cell 
layer and a fibrovascular supporting stroma. Koilocytes are 
present in stratum granulosum and upper stratum spinosum. 
BPV-1 positive, WS positive. 
CASE NO. 464-90: Hyperortho-parakeratotic, acanthotic 
stratified epithelial ridges disposed in papillary 
projections with replication of the basal cell layer and a 
fibrovascular supporting stroma. Koilocytes are present in 
stratum spinosum. BPV-1 positive, ws negative. 
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CASE NO. 242-90: Hyperparakeratotic, acanthotic stratified 
squamous epithelial fused ridges, obliterating the stromal 
rete pegs with replication of the basal cell layer. 
Acanthosis is remarkable. Koilocytes are present in stratum 
spinosum. BPV-positive, WS positive. 
CASE NO. 1067-89: Hyperorthokeratotic, acanthotic stratified 
squamous epithelium disposed in sharp papillary projections 
with replication of the basal cell layer and a fibrous 
supporting stroma. Many large koilocytes are present in 
stratum granulosum. BPV-1 positive, ws positive. 
CASE NO. 869-89: Parakeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections with 
replication of the basal cell layer and a fibrous supporting 
stroma. Koilocytes are present in stratum spinosum. BPV-1 
positive, WS positive. 
CASE NO. 780-89: Parakeratotic, acanthotic stratified 
squamous epithelium showing papillary hyperplasia, with 
replication of the basal cell layer and a dense fibrous 
supporting stroma. Few koilocytes are present in stratum 
granulosum. BPV-1 positive, ws positive. 
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CASE NO. 734-89: Orthokeratotic, acanthotic stratified 
squamous epithelial ridges disposed in papillary projections 
with basal cell replication and a fibrovascular supporting 
stroma. Many large koilocytes are present in stratum 
granulosum and spinosum. BPV-1 positive, WS positive. 
CASE NO. 713-89: Hyperparakeratotic, acanthotic stratified 
squamous epithelial attenuated ridges disposed in short 
papillary projections with replication of a hyperchromatic 
basal cell layer, mitotic activity in the basal and 
suprabasal cell layers and a fibrous supporting stroma. 
Koilocytes are present in stratum spinosum. BPV-1 positive, 
WS negative 
CASE NO. 674-89: orthokeratotic, acanthotic stratified 
squamous epithelial sharp, fused ridges disposed in 
papillary folds and supported by a fibrous stroma. 
Koilocytes are present in stratum spinosum. BPV-1 positive, 
WS positive. 
CASE NO. 657-89: Parakeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections with 
replication of the basal cell layer and a f ibrovascular 
supporting stroma. Koilocytes are present in stratum 
spinosum. BPV-1 positive, WS positive. 
CASE NO: 645-89: Orthoparakeratotic, acanthotic stratified 
squamous epithelium disposed in sharp papillary projections 
with replication of the basal cell layer and a fibrous 
supporting stroma. BPV-1 positive, WS positive. 
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CASB NO. 637-89: Parakeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections with 
basal cell replication and a fibrous supporting stroma. Many 
koilocytes are present in stratum granulosum and spinosum. 
BPV-1 positive, WS positive. 
CASB NO: 285-89: Hyperorthokeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections with 
basal cell layer replication and a fibrous supporting 
stroma. Many large koilocytes are present in stratum 
granulosum and spinosum. BPV-1 positive, WS positive. 
CASB NO. 174-89: Parakeratotic, acanthotic, stratified 
squamous epithelium disposed in papillary projections with 
replication of the basal cell layer and a fibrovascular 
supporting stroma. BPV-1 positive, WS negative. 
CASB NO. 131-89: Parakeratotic, acanthotic stratified 
squamous epithelium with a slight corrugated surface, 
replication of the basal cell layer and supported by a 
fibrovascular lamina propia with projecting connective 
tissue pegs, deep to which are neurovascular bundles and 
interstitial fibrous tissue. Large koilocytes are present 
in stratum spinosum. BPV-1 positive, WS positive. 
CASB NO. 71-89: Parakeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projectios with 
replication of the basal cell layer and a f ibrovascular 
supporting stroma. Koilocytes are present in stratum 
granulosum and spinosum. BPV-1 positive, WS positive. 
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CASE NO. 970-88: Hyperorthokeratotic, acanthotic stratified 
squamous epithelium disposed in papillary projections with 
replication of the basal cell layer and a f ibrovascular 
supporting stroma. Koilocytes are present in stratum 
granulosum. BPV-1 positive, ws positive. 
CASE NO. 934-88: Parakeratotic, acanthotic stratified 
squamous epithelial broad ridges disposed in papillary 
projections with frequent mitotic activity and replication 
of the basal cell layer, supported by a delicate 
fibrovascular stroma. Few koilocytes are present in stratum 
granulosum. BPV-1 positive, WS positive. 
CASE NO: 1076-87: Parakeratotic, acanthotic hyperplastic 
stratified squamous epithelial broad fuse ridges with 
mitotically active basal and suprabasal cells and a fibrous 
supporting stroma. Koilocytes are present in stratum 
granulosum. BPV-1 positive , WS negative. 
CASE NO. 735-87: Para-orthokeratic, acanthotic elongated 
ridges of stratified squamous epithelium with replication of 
the basal cell layer and a delicate f ibrovascular stroma 
supporting the capillary projections of epithelia. 
Koilocytes are present in stratum granulosum and spinosum. 
BPV-1 positive, WS positive. 
CASE NO. 189-87: Hyperparakeratotic, acanthotic, stratified 
squamous epithelium disposed in papillary projections with 
basal cell replication and a mature f ibrovascular supporting 
stroma. Koilocytes are present in stratum granulosum and 
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spinosum, which show chromatin material in the periphery or 
poikilocytosis. BPV-1 positive, WS negative. 
CASE NO. 1106-86: Parakeratotic, acanthotic, folds of 
stratified squamous epithelium disposed in sharp papillary 
projections with replication of the basal cell layer and a 
fibrovascular supporting stroma. Koilocytes are present in 
stratum granulosum and spinosum. BPV-1 positive, WS 
positive. 
CASE NO. 798-86: Parakeratotic, attenuated, flattened ridges 
of stratified squamous epithelium with a transition to sharp 
papillary folds and hyperparakeratosis with basal cell layer 
replication and a supporting fibrovascular core. Huge 
koilocytes are present in stratum granulosum. BPV-1 
positive, WS positive. 
CASE NO. 765-86: Parakeratotic, acanthotic, stratified 
squamous epithelium disposed in papillary projections with 
basal cell layer replication and supported by a 
fibrovascular stroma showing neurovascular bundles. Slight 
reactive hyperplasia is seen with a whorling pattern of a 
benign dyskeratosis near the superficial surface of the 
differentiating epithelium. Koilocytes are present in 
stratum granulosum and spinosum. BPV-1 positive, WS 
positive. 
CASE NO. 578-86: Hyperparakeratotic, acanthotic, stratified 
squamous epithelium disposed in papillary folds, with 
replication of the basal cell layer, which shows compressed 
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keratinocytes indicating a reactive hyperplasia and 
supported by a fibrovascular stroma. Koilocytes are present 
in stratum spinosum and granulosum and melanocytes in the 
stratum basale. BPV-1 positive, WS negative. 
CASE NO. 485-86: Ortho-parakeratotic, acanthotic stratified 
squamous epithelium disposed in numerous papillary ridges 
with piling up of parakeratin in some areas and replication 
of the basal cell layer, which shows numerous attenuated 
ridge like projections into the supporting f ibrovascular 
stroma. Koilocytes are present in stratum granulosum and 
spinosum. BPV-1 positive, WS positive. 
CASE NO. 1065-85: Parakeratotic, acanthotic, stratified 
squamous epithelial elongated ridges disposed in sharp 
papillary projections with replication of the basal cell 
layer and a fibrovascular supporting stroma. BPV-1 positive, 
ws negative. 
CASE NO. 962-85: Ortho-parakeratotic, acanthotic, stratified 
squamous broad, fused epithelial ridges, disposed in 
papillary projections with replication of the basal cell 
layer and a fibrovascular supporting stroma. Large 
koilocytes present in the stratum granulosum, some with 
pyknotic nuclei. BPV-1 positive, WS positive. 
CASE NO. 902-85: Hyperparakeratotic, stratified squamous 
epithelium disposed in sharp papillary folds and supported 
by a fibrovascular stroma. Koilocytes are present in 
stratum granulosum and spinosum. BPV-1 positive, WS 
positive. 
CASB NO. 892-85: Orthokeratotic, acanthotic, stratified 
squamous epithelium disposed in papillary folds with 
replication of the basal cell layer and a mature 
fibrovascular supporting stroma. BPV-1 positive, WS 
negative. 
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CASE NO. 816A-85: Ortho-parakeratotic, acanthotic, 
stratified squamous epithelium disposed in papillary 
projections with replication of the basal cell layer which 
appears columnar or cuboidal and palisading as the 
suprabasal cell layer shows slight variation of the 
orientation, supported by a loosely arranged mucoid 
connective tissue containing numerous vascular channels. 
Basal and suprabasal cells show frequent morphologically 
normal mitotic figures. Few localized koilocytes are present 
in stratum granulosum. BPV-1 positive, WS positive. 
CASE NO. 816B-85: Parakeratotic, acanthotic, stratified 
squamous reactive hyperplastic epithelial ridges with basal 
and suprabasal cell replication and a fibrovascular 
supporting stroma. As the papillary projections arise in a 
branching manner, the surface of the epithelium shows ortho-
parakeratinization. One area of the mucosa shows mucoid-like 
loosely arranged fibrous connective tissue. Many koilocytes 
are present in stratum granulosum and spinosum. BPV-1 
positive, WS positive. 
CASE NO. 782-85: Parakeratotic, acanthotic, stratified 
squamous broad and narrow, sharp, elongated epithelial 
ridges disposed in papillary projections with basal cell 
layer replication and a fibrovascular supporting stroma. 
Koilocytes are present in stratum granulosum, with a 
centrally placed nucleus. BPV-1 positive, WS positive. 
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CASE NO. 481-85: Parakeratotic, acanthotic, stratified 
squamous broad epithelial ridges disposed in narrow 
papillary projections with replication of the basal cell 
layer and a fibrovascular supporting stroma. The basal and 
suprabasal cell show many hyperchromatic nuclei, infrequent, 
but morphologically normal mitotic figures. BPV-1 positive, 
WS negative. 
CASE NO. 627-85: Parakeratotic, acanthotic, stratified 
squamous epithelium disposed in raised papillary projections 
with replication of the basal cell layer, showing occasional 
morphologically normal mitotic figures and a fibrovascular 
supporting stroma. BPV-1 positive, WS negative. 
CASE NO. 479-85: Ortho-parakeratotic, stratified squamous 
epithelium disposed in sharp papillary ridges, with 
replication of the basal cell layer and a fibrous supporting 
stroma. The basal and suprabasal cells have multiple 
nucleoli, but few and morphologically normal mitotic 
figures. Some areas show hyperkeratosis with intercellular 
filaments characteristic of Candida Albicans. BPV-1 
positive, ws positive. 
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CASE NO. 268-85: Orthokeratotic, acanthotic, stratified 
squamous fused, broad, epithelial ridges, supported by a 
fibrovascular stroma. At one point, there rises papillary 
projections of the epithelium showing hyperorthokeratosis 
with long, sharp, extending epithelial ridges, supported by 
a branching fibrovascular connective tissue. Koilocytes are 
present in stratum granulosum and spinosum. BPV-1 positive, 
WS negative. 
CASE NO. 160-85: Parakeratotic, stratified squamous 
epithelium disposed in sharp papillary folds and supported 
by a fibrovascular stroma. Few koilocytes are present in 
stratum granulosum. BPV-1 positive, WS positive. 
CASE NO. 655-83: Ortho-parakeratotic, acanthotic, 
stratified squamous epithelium disposed in papillary ridges, 
showing converging borders and supported by a f ibrovascular 
stroma. Koilocytes are present in stratum granulosum and 
spinosum. BPV-1 positive, WS positive. 
CASE NO. 623-82: Hyperparakeratotic, acanthotic, stratified 
squamous epithelium, disposed in sharp papillary ridges with 
basal cell layer replication and a f ibrovascular supporting 
stroma. Koilocytes are present in stratum granulosum and 
spinosum. BPV-1 positive, ws positive. 
CASE NO. 244-82: Hyperparakeratotic, stratified squamous 
epithelium disposed in sharp, papillary folds that converge 
inward and supported by a f ibrovascular stroma with some 
striated muscle bundles. The stratum granulosum is thick, 
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showing heavy keratin/hyaline granules. Koilocytes are 
present in stratum corneum. BPV-1 positive, WS positive. 
CASE HO. 153-82: Hyperparakeratotic, acanthotic, stratified 
squamous broad, fused epithelial ridges disposed in 
papillary projections with replication of the basal cell 
layer and a fibrovascular supporting stroma. BPV-1 positive, 
ws positive. 
CASE HO. 143-82: Hyperparakeratotic, acanthotic, broad, 
fused ridges, disposed in sharp, papillary folds with basal 
cell replication and a fibrous supporting stroma. The 
stratum spinosum shows multiple nucleolar like inclusions 
within the nucleus of the cells. BPV-1 positive, ws 
negative. 
CASE HO. 728-81: Hyperparakeratotic, stratified squamous 
long, sharp epithelial ridges with plexiform pattern with 
basal cell layer replication and a mature fibrovascular 
supporting stroma. Many of the epithelial cells show 
characteristic nuclear vesiculation with residual single or 
multiple nucleoli-like structures resembling inclusions. The 
stratum spinosum shows areas of cytolysis with loss of the 
entire epithelial cell at sites containing infiltrating 
monocytes and neutrophils. Koilocytes are present in the 
stratum granulosum. BPV-1 positive, WS negative. 
CASE HO. 200-80: Hyperparakeratotic, acanthotic stratified 
squamous epithelial ridges disposed in papillary projections 
and supported by a mature fibrovascular stroma. The basal 
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cell layer shows some crowding of the epithelium, nuclear 
edema and prominent nucleoli. The stratum spinosum shows 
ocassional benign dyskeratotic cells and koilocytes with 
contraction of the nucleus towards the cell membrane and 
prominent multiple nucleoli. BPV-1 positive, ws positive. 
CASE HO. 165-79: Hyperparakeratotic, acanthotic stratified 
epithelium disposed in deep papillary folds and supported by 
a fibrovascular stroma. BPV-1 positive, WS negative. 
CASE HO. 213-78: Hyperortho-parakeratotic, acanthotic, 
stratified squamous epithelium disposed in short papillary 
folds and supported by a fibrous stroma with mucous glands. 
The basal cell layer shows slight lymphocyte infiltration 
and hydropic degeneration. The basement membrane is 
thickened, but in some areas ill-defined due to lymphocytic 
infiltration. BPV-1 positive, WS negative. 
CASE HO. 155-78: Hyperparakeratotic, acanthotic, stratified 
squamous epithelium disposed in sharp papillary folds with 
basal cell layer replication and a mature f ibrovascular 
supporting stroma. Few koilocytes are present in stratum 
granulosum. BPV-1 positive, WS positive. 
CASE HO. 315-75: Hyperorthokeratotic, acanthotic, stratified 
squamous epithelium disposed in papillary folds and 
supported by a mature, dense, fibrovascular stroma. BPV-1 
positive, WS negative. 
CASE HO. 557-70: Hyperparakeratotic, stratified squamous 
epithelium disposed in many papillary folds with basal cell 
layer replication and a fibrous supporting stroma. Few 
koilocytes are present in the stratum granulosum. BPV-1 
positive, WS negative. 
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MATERIALS AND METHODS 
I. AVIDIN-BIOTIN-PEROXIDASE COMPLEX FOR IMMUNOHISTOCHEMISTRY 
PRINCIPLE 
The method is based on antigen-antibody reactions in 
order to detect the location of viral proteins in the cells 
of formalin-fixed, paraffin-embedded oral squamous papilloma 
specimens mounted on microscope slides. The technique 
involves the use of a primary antibody to react with the 
tissue antigenic sites, a biotin-labeled secondary antibody 
against immunoglobulin of the primary species (IgG or IgM), 
followed by the addition of a freshly prepared complex of 
biotin-labeled horseradish peroxidase (HRP) and modified 
egg-white avidin. 
The primary antibody is the rabbit anti-bovine 
papillomavirus type 1 (BPV-1) which was obtained by the 
immunization of a rabbit with bovine papillomavirus type 1 
collected from cutaneous fibropapillomas of cattle. BPV-1 is 
a readily available source of large quantities of 
papillomavirus. The antiserum obtained when BPV-1 is used as 
an antigen is less likely to give false reactions with 
endogenous intranuclear proteins and DNA in human tissue 
than is the antiserum derived from human papillomavirus 
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(HPV). The virus was treated with 0.24M 2-mercaptoethanol 
and 1% sodium dodecyl sulfate (SOS), heated to 68°C for 2 
minutes, diluted with three volumes of saline and mixed with 
an equal volume of Freund's complete adjuvant. A rabbit was 
cutaneously inoculated with the above purified, previously 
characterized BPV-1 with 480, 240 and 120 mg of virus 
protein at days o, 15 and 28. The rabbit was bled at day 38. 
This hyperimmune serum (anti-BPV-1 [SOS]) is reactive with 
PV positive cutaneous and mucosal papillomas from a variety 
of species, (human, dog, cow, rabbit, deer, and horse). This 
cross reaction is due to the presence of genus-specific, 
common antigenic determinants in the major capsid proteins 
of papillomaviruses. 116 
The biotin-labeling of anti-rabbit IgG (secondary 
antibody) and peroxidase was accomplished with the 
incorporation of biotin moieties into immunoglobulin (Ig) or 
peroxidase (PO) molecules by the use of biotinyl-N-hydroxy-
succinimide (BNHS). Biotinylation of Ig and PO improves 
sensitivity and reduces time by increasing the availability 
of biotin-binding sites and improving the ability to bind 
avidin molecules in the avidin-biotin-peroxidase complex. 
This is due to the great affinity of avidin, a 68,000 
molecular weight glycoprotein found in egg white, for 
biotin, a small vitamin molecule, one mole of avidin binds 
up to four moles of biotin with a dissociation constant of 
10-15M. During the formation of the avidin-biotin-peroxidase 
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biotin, a small vitamin molecule, one mole of avidin binds 
up to four moles of biotin with a dissociation constant of 
10-15M. During the formation of the avidin-biotin-peroxidase 
complex, avidin acts as a bridge between biotin-labeled 
peroxidase and at the same time biotin-labeled peroxidase 
molecules, which contain several biotin moities, serve as a 
link between the avidin molecules. Consequently, a "lattice" 
complex containing several peroxidase molecules is likely 
formed. Binding of this complex to the biotin moities 
associated with the secondary antibody results in a high 
staining intensity. 117 Visualization of the viral proteins 
is accomplished by the histochemical peroxidation of 
diaminobenz idine. 118 
INTERPRETATION OF STAINING 
Staining occured predominantly intranuclear in a focal 
or diffuse pattern. Perinuclear cytoplasmic staining of 
koilocytotic cells was also seen in the nuclei and 
cytoplasm. The positive signals appeared predominantly, as 
brown or dark brown staining of nuclei in koilocytotic 
cells, in a focal or diffuse pattern, although, cytoplasmic 
staining was also seen. 
MATERIALS 
SPECIMENS 
One hundred lesions subjected to routine hematoxylin 
and eosin stain and diagnosed as "oral squamous papillomas", 
were retrieved from the files of the Oral Pathology 
Laboratory, Dental School, Loyola University Medical Center. 
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The specimens were formalin-fixed, paraffin-embedded, from 
the years of 1970 to 1992 and were categorized based on 
their size as: 
a. Good size specimens, 3 or more mm. 
b. Moderate size specimens, 2 or 3mm. 
c. Poor sized specimens, less than 1 mm. 
Only those categorized as good and moderate sized specimens 
were selected for the purpose of this investigation. 
REAGENTS 
1. Phosphate-buffered saline {PBS), lOX concentration 
Sodium phosphate monobasic monohydrate 
Sodium phosphate dibasic, anhydrous 
Sodium chloride 
Tween 20 
Deionized water, to make: 
Diluted 1:10 with water to make the working solution. 
2. 1% Albumin-saline {PBS-BSA) 
Bovine serum albumin, fraction V 
Tween 20 
PBS 
Mixed and added, as preservative: 
Sodium azide 
3. Primary antibody in PBS/BSA containing 
1% normal goat serum Rabbit Anti-Bovine 
Papillomavirus {BPV-1) 














Albumin, fraction v, source bovine blood 





The above concentration was used for a batch of 30 slides. 
The amount of solution to be prepared depends on the amount 
of slides being processed. Albumin and sodium chloride were 
used in order to decrease background. 
4. Streptavidin-horseradish peroxidase kits 
Obtain from Kirkegaard-Perry Laboratories 
Cat. No. 71-00-18 (mouse primary) 
71-00-19 (rabbit primary) 
Each kit contained blocking serum, biotinylated secondary 
antibody and streptavidin-HPR conjugate. 
5. Diaminobenzidine (DAB) substrate 
a. Buffer 
Ammonium acetate 3.85 g 
Deionized water 900 mL 
Added citric acid, 10%, to obtain pH 5.5. 
Added water to make 1 L. Store at 4° c. 
b. Substrate solution 
Two tablets (lOmg each) DAB (Sigma D-5905) were added 
for each 50 mL of buffer at room temperature, allowed 
to dissolve and filtered. Just before using, 90 µL 3% 
H20 2 per 50 mL was added. After use, substrate 
solution was poured into bottle containing sodium 
hypochlorite solution, treated for 27 hours and then 
disposed via sink. 
5. Hematoxylin 
Harris-type hematoxylin solution (non-mercuric), was 
obtained from Newcomer Supply (Cat. No. 1201). 
6. Pepsin 
One packet of Dako pepsin (Cat No. S3002), was added to 
200 mL of deionized water. When dissolved, 50 mL lN HCL 
was added. store at -20°c. 
CONTROLS 
Controls may be of several kinds: 
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1. A positive control (type 1), tissue specimen which is 
treated together with the patient specimen and monitored 
for typical appearance. 
2. A negative control (type 2), for which the patient 
specimen is treated as usual, but omitting the primary 
antibody. Nonspecific positive reactions such as 
endogenous peroxidase would be revealed in such a 
control. 
3. Dilution controls (type 3), in which a series of graded 
dilutions of primary antibody are applied to a control 
specimen to assess the performance of a particular brand 
or lot of antibody in comparison to previous or expected 
results. 
Type 1 controls are performed, usually, with one control 
slide being included per antigen tested per case. 
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Representative samples are obtained, processed according to 
standard protocols and tested in the procedure before used. 
Type 2 controls are included in instances where increased 
background might be expected to occur or in the case of 
tissues bearing pigment that might be confused with reaction 
product. 
Type 3 controls are performed as needed and the results 
recorded in a log book showing the antibody, its dilution 
and any other pertinent information. 
The type of control used in this investigation, were 4 
micron thick sections of buffered 10% formalin-fixed, 
paraffin-embedded papilloma mounted on poly-L-lysine coated 
microscope slides, obtained from DAKO Corporation (Catalog 
No. T1211). Positive anti-papillomavirus antigen nuclei, 
were found more predominantly in stratum granulosum than in 
stratum basale. Also stained are pyknotic nuclei and nuclear 
breakdown products, as well as perinuclear tissue of stratum 
corneum. Any non-specific background staining of 
cytokeratins was ignored. 
OTHER MATERIALS USED 
DAKO Rabbit Anti-Bovine Papillomavirus (BPV-1), (cat. 
No.B580) 
Albumin in powder 
100%, 70%, 95% alcohol, and acid alcohol 
Ammonia water 
Concentrated normal goat serum 
Deionized water 
1N HCL 
Sodium chloride in powder 
Xylene 
Absorbent wipes 
Brushes of different sizes 
Coplin Jars 
Covers lips 
Droppers and pump for droppers 
Gloves 
Humidified chamber for slide incubation 
Mounting medium 
37°C oven and 60°C oven 
Permanent ink markers 
2-8°C refrigerator 
Silanized microscope slides 
Staining racks 
Standard light microscope 
Tweezers 
38°C water bath 
PROCEDURE 
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1. 3 µm sections of paraffin-embedded tissue were cut and 
mounted on glass slides that have been coated with 
organosilane. Water bath temperature was monitored at 
38°C. 
2. Sections were air-dried at 20-37°C. 
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3. All slides were pre-heated 20-30 minutes at 60°C., then 
transfered directly to xylene without cooling and 
treated with three changes of xylene, 5 minutes each. 
4. Slides were rinsed in two changes of absolute alcohol. 
In order to inactivate/extract endogenous peroxidase 
and hemoprotein, slides were then immersed in absolute 
ethanol with 0.075% HCL for 15 minutes, (0.1 mL cone. 
acid/50 mL). 
5. Sections were brought through graded alcohols (95%-70%) 
to water and then to PBS. No enzyme treatment was 
required. 
6. In a moist chamber, slides were covered with the 
blocking reagent (normal goat serum), provided in the 
kits and left at room temperature for 30 minutes. 
7. Sections were blotted quickly on filter paper and 
covered with a solution of the primary antibody in 
PBS/BSA containing 1% normal goat serum. Slides were 
placed back in the moist chamber and placed in the 
refrigerator, the level of the chambers checked and 
left incubated for 15-18 hours (or longer if needed). 
8. Incubation in antibody solutions at this and subsequent 
stages was followed by washing in three changes of PBS, 
5 minutes each, to remove unreacted antibody. 
9. Biotinylated antibody against IgG of the species in 
which the primary antibody was prepared (prediluted or 
prepared from concentrated antibody) was applied to the 
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sections for 30 minutes at ambient temperature. In this 
particular case goat anti-rabbit IgG was used. 
10. After washing as before, sections were covered with 
streptavidin-peroxidase reagent in the moist chamber 
for 30 minutes at ambient temperature. 
11. Sections were washed in PBS as before, then rinsed with 
deionized water and placed in peroxidase substrate 
solution (DAB) for 3 minutes in a dark chamber. 
12. After thorough washing in water, the sections were 
counterstained with Harris hematoxylin for 4 minutes, 
differentiated in acid alcohol (1% HCl in 70% ethanol), 
blued in 0.1% ammonia water, washed in running tap 
water, dehydrated, cleared and mounted in AccuMount. 
DEHYDRATION PROCEDURE: 70%-95%-95%-100%-100% alcohol for 3 
minutes each and three changes of xylene for 5 minutes each. 
Note: The entire procedure was performed according to 
protocol prepared by Robert Martinez, 
(Immunohistochemistry Laboratory, Loyola University 
Medical Center) and adapted to this investigation. 
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II. IN SITU HYBRIDIZATION FOR BPV TYPE WIDE SPECTRUM PROBE, 
BPV TYPE SPECIFIC PROBES, POSITIVE AND NEGATIVE CONTROL 
PROBES. 
PRINCIPLE 
The "in situ" hybridization technique is used to detect 
the presence of human papillomavirus (HPV) DNA sequences 
within the nuclei the epithelial cells of formalin-fixed, 
paraffin-embedded, tissue sections of oral squamous 
papilloma specimens, mounted on slides. The morphology of 
the tissue is preserved with this technique making it 
possible to relate the presence of HPV with pathologic 
changes and at the same time enables the investigator to 
visualize the exact location of viral DNA. 
Tissue sections are first de-paraff inized and then 
digested with a proteolytic enzyme, pepsin, in order to 
remove proteins that mask DNA, to increase the accessibility 
of HPV DNA sequences and to allow probes to permeate the 
tissue sections more effectively. Next, the double-stranded 
HPV DNA sequences and biotinylated probes are simultaneously 
denatured at a temperature of 90°C, by placing the slides on 
a heating block, the probe is allowed to hybridized the HPV 
DNA sequences within the tissue specimen. A stringent wash 
solution is then used to remove excess probe, and this 
stringent wash solution contains a blocking agent that 
blocks nonspecific binding sites on the tissue which may 
otherwise react with the detection reagents. After the 
stringent wash, the streptavidin alkaline phosphatase 
conjugate is used, which binds to the biotin groups on the 
hybridized probe molecules. The site of hybridization is 
visualized by the colorimetric reaction of the alkaline 
phosphatase enzyme conjugate with its substrate, BCIP (5 
bromo-4 chloro-3 indolyl phosphate) and the concomitant 
reduction of NBT (nitro blue tetrazolium), this reaction 
results in the deposition of an insoluble blue-purple 
product at the site of hybridization. 
PROBES 
HPV types 6, 11, 16, 18, 31, 33, wide spectrum HPV, 
positive control (human DNA) and negative control (plasmid 
DNA), biotinylated DNA probes were used. 
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Biotinylation of the probe is accomplished through the non-
radioactive labeling of the nucleic acids with biotin 
(vitamin H). The biotinylated nucleotide are enzymatically 
incorporated into the probe molecule by the nick translation 
DNA labelling method. 119 The biotin molecule is covalently 
bound to the C-5 position of the pyrimidine ring through an 
allylamine linker arm in the nucleotide analogs of 
deoxyuridine triphosphate and 5-(3-amino) allyl uridine 
triphosphate. These analogs function as substrates for a 
series of RNA or DNA polymerases in vitro. The interactions 
of biotin and avidin have one of the highest binding 
constant (Kcus=l0-15 ) known. The use of streptavidin (a 
modified avidin tetrameric protein) coupled (or conjugated) 
to the enzymes alkaline phosphatase and peroxidase which act 
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as indicator molecules, enables the detection of minute 
quantities of biotin120 in the biotinylated probes. Thus, 
the highest sensitivities for the detection of biotinylated 
probes are achieved by using streptavidin, which unlike 
avidin exhibits very low nonspecific binding. 121 
WIDE SPECTRUM HPV BIOTINYLATED DNA PROBE 
This double-stranded DNA probe is a nick-translated 
probe prepared from human papillomavirus (HPV) DNAs which 
are cloned into plasmid DNA vectors from phage vectors. The 
targets for this probe are the genomic DNAs of HPV types 6, 
11, 16, 18, 30, 31, 33, 35, 45, 51 and 52. When tested at 
intermediate stringency (Tm -20°C.) in a non-radioactive 
Southern blot hybridization using 50 ng of cloned HPV DNA's 
as targets, this probe hybridizes to the DNA of HPV types 6, 
11, 16, 18, 30, 31, 33, 35, 45, 51 and 52. The probe is used 
for the detection of HPV DNA in tissue specimens by "in 
situ" hybridization (ISH) and when used in the recommended 
ISH procedure, the probe demonstrates reactivity only with 
tissues infected with HPV. 122 
HPV TYPE 6 BIOTINYLATED DNA PROBE 
This type-specific double-stranded DNA probe is a nick-
translated probe prepared form sub-genomic clones of human 
papillomavirus (HPV) type 6 which are cloned into plasmid 
vectors. The targets for this probe include regions of the 
ES and L2 ORF's (open reading frames) of HPV type 6. When 
tested by non-radioactive Southern blot hybridization at 
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high stringency (Tm -1o·c.) against 100 ng of cloned HPV DNA 
from types 6, 11, 16, 18, 30, 31, 33, 3S, 4S, Sl and S2 this 
probe is specific for HPV-6 • 123 
BPV TYPE 11 BIOTINYLATED DNA PROBE 
This type-specific double-stranded DNA nick-translated 
probe is prepared from sub-genomic clones of human 
papillomavirus (HPV) type 11 which are cloned into plasmid 
vectors. The targets for this probe include regions of the 
ES and L2 ORF (open reading frames) of HPV 11. When tested 
by non-radioactive Southern blot hybridization at high 
stringency (Tm -1o·c.) against 100 ng of cloned HPV DNA from 
types 6, 11, 16, 18, 30, 31, 33, 3S, 4S, Sl and S2, this 
probe is specific for HPV 11. 124 
BPV TYPE 16 BIOTINYLATED DNA PROBE 
This type-specific double-stranded DNA nick-translated, 
is prepared from sub-genomic clones of human papillomavirus 
(HPV) type 16 which are cloned into plasmid vectors. The 
targets for this probe include regions of the El, E2, E4, 
ES, E6 and E7 ORF's (open reading frames) as well as the URR 
(upstream regulatory region), of HPV type 16 when tested by 
non-radioactive Southern blot hybridization at high 
stringency (Tm - lO"C.) against 100 ng of cloned HPV DNA 
from types 6, 11, 16, 18, 30, 31, 33, 3S, 4S, Sl and S2 this 
probe is specific for HPV 16 • 125 
BPV TYPE 18 BIOTINYLATED DNA PROBE 
This type-specific double-stranded DNA nick-translated 
6S 
probe is prepared from sub-genomic clones of human 
papillomavirus (HPV) type 18 which are cloned into plasmid 
vectors. The targets for this probe include regions of the 
E2, ES, E6, E7 and L2 ORF's (open reading frames) as well as 
the URR (upstream regulatory region) of HPV type 18. When 
tested by non-radioactive Southern blot hybridization at 
high stringency (Tm - l0°C.) against 100 ng of cloned HPV 
DNA from types 6, 11, 16, 18, 30, 31, 33, 3S, 4S, Sl and S2, 
this probe is specific for HPV 18. The probe is used for the 
detection of HPV type 33 DNA in tissue specimens by "in 
situ" hybridization and when used in the recommended ISH 
procedure the probe demonstrates reactivity only with 
tissues infected with HPV 18. 126 
HPV TYPE 31 B:IOTJ:NYLATED DNA PROBE 
This type-specific double-stranded DNA nick-translated 
probe prepared from sub-genomic clones of human 
papillomavirus (HPV) type 31 which are cloned into plasmid 
vectors. The targets for this probe include regions of the 
E2, ES and L2 ORF's (open reading frames) as well as the URR 
(upstream regulatory region) of HPV type 31. When tested by 
non-radioactive Southern blot hybridization at high 
stringency (Tm - l0°C.) against 100 ng of cloned HPV DNA 
from types 6, 11, 16, 18, 30, 31, 33, 3S, 4S, Sl and S2, 
this probe is specific for HPV 31. The probe is used for the 
detection of HPV type 31 DNA in tissue specimens by "in 
situ" hybridization (ISH) and when used in the recommended 
ISH procedure, the probe demonstrates reactivity only with 
tissues infected HPV 31. 127 
HPV TYPE 33 BIOTINYLATED DNA PROBE 
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This type-specific double-stranded DNA nick-translated 
probe prepared from sub-genomic clones of human 
papillomavirus (HPV) type 33 which are cloned into plasmid 
vectors. The targets for this probe include regions of the 
E2, ES, E6 and L2 ORF's (open reading frames) as well as the 
URR (upstream regulatory region) of HPV type 33. When tested 
by non-radioactive Southern blot hybridization at high 
stringency (Tm -10°c.), against 100 ng of cloned HPV DNA 
from types 6, 11, 16, 18, 30, 31, 33, 45, 51 and 52, this 
probe is specific for HPV 33. The probe is used for the 
detection of HPV type 33 DNA in tissue specimens by "in 
situ" hybridization and when used in the recommended ISH 
procedure the probe demonstrates reactivity only with 
tissues infected with HPV 33 • 128 
The detection sensitivity of wide spectrum and type-
specific HPV probes is approximately 100 molecules of target 
sequences as measured by "in situ" hybridization and as 
measured with an analogous probe on HPV-infected, cultured 
cells. When assayed under recommended protocol none of the 
probes reacted with normal human nuclear DNA when probed by 
"in situ" hybridization, or with E. Coli DNA when tested by 
blot hybridization. 
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POSITIVE CONTROL (HUMAN DNA) BIOTYNILATED DNA PROBE 
Positive control (human DNA) biotinylated DNA probe is 
a double stranded human DNA nick-translated probe prepared 
from total human DNA which has been purified from cultured 
human cells. This probe targets total genomic human DNA. The 
probe is used for the detection of human DNA in the nuclei 
of tissue specimens by "in situ" hybridization, it is only 
intended for use on human tissues. The detection sensitivity 
of this probe when assayed by "in situ" hybridization when 
using the recommended protocol, shows most normal diploid 
nuclei stained positively . 129 
NEGATIVE CONTROL (PLASMID DNA) BIOTINYLATED DNA PROBE 
Negative control (plasmid DNA) biotinylated DNA probe 
is a double-stranded plasmid DNA nick-translated probe 
prepared from pUC18 plasmid DNA which has been purified from 
cultured E. Coli cells. This probe targets total plasmid DNA 
from pUC18. This probe is used as a negative control to 
asses the levels of background staining and non-specific 
probe binding on formalin-fixed, paraffin-embedded tissue 
specimens during "in situ" hybridization. This probe is 
intended for use on human tissues only. When assayed by "in 
situ" hybridization using the recommended protocol, no 
staining was observed on normal formalin fixed, paraffin-
embedded tissues. 130 
MATERIALS 
REAGENTS 
The following materials, sufficient for processing 50 
slides, are included in the DAK09 In Situ Hybridization 
Detection System K601 and K602. 
Quantiy 
2 Bottle 2: 
Description 
15 ml Stringent Wash concentrate (SOX) 
containing o. 015m NaN3 • 
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1 Bottle 3: 15 ml Streptavidin, Alkaline Phosphatase 
conjugated, in Tris buffer (lX) 
containing 0.015m NaN3 • 
1 Bottle 4: 15 ml BCIP/NBT substrate/chromogen 
solution (lX) 
1 Plastic pipette for Stringent Wash dilution 
1 5 ml calibrated test tube for Stringent Wash dilution 
Pepsin/HCL Digestion reagent 
Tris-buffered Saline (TBS) 
OTHER MATERIALS USED 
Absorbent wipes 
Alcohol solutions (95 and 100%) 
Biotinylated probes 
Covers lips 
Deionized or distilled water 
Gloves 
90°C heating plate or oven 
Humidified chamber for slide incubation 
3 7°C incubator 
40-60°C incubator or water bath 
Mounting medium 
60°C oven 
Silanized-treated microscope slides 
Staining racks or coplin jars 
Standard light microscope 
Xylene 
PREPARATION OF REAGENTS 
The following reagents required preparation prior to 
beginning the procedure. 
A. Pepsin/HCI Digestion reagents. 
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This reagent is required for "in situ" procedures using 
DNA hybridization on formalin-fixed tissues. Pre-measured 
pepsin packets, Code No. S3002 are available from DAKO. 
The entire contents of one of the pepsin packets were 
dissolved in 250 ml on 0.2N hydrochloric acid. The 
digestion reagents were heated at 37° C using a water 
bath just prior to use. Excess solution was stored 
immediately at 20° c. 
B. Tris-buffered Saline (TBS). 
Pre-measured TBS packets, Code No. S3001 are available 
from DAKO. The entire contents of one TBS powder were 
dissolved package in 1 liter of deionized or distilled 
water. The diluted solution is stable for one month a 
4°C. 
c. Stringent Wash Solution. 
Stringency requirements will vary depending on probe 
composition (%G + C) and the degree of homology between 
probe and target sequences. Generally, a wash of 
intermediate stringency should be tried first. If the 
resultant background is too high, stringency should be 
increased by raising the temperature of the wash; if 
signal intensity is too weak, stringency should be 
lowered by decreasing the wash temperature. 
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The chart below was used to select stringency conditions 
when using nick-translated DNA probes of approximately 50 % 
G + c content on formalin-fixed, paraffin-embedded tissues. 







The stringent wash temperature used for the Wide Spectrum 
Probe was 48°C, the same as for the positive and negative 
controls that accompanied the procedure. 
The stringent wash temperature used for each of the Type 
Specific Probes was 58°C, the same as for the positive and 
negative controls that accompanied the procedure. 
The dropper tip from Bottle 2 was removed. With the use of 
the plastic pipette and calibrated test tube, 1 ml of the 
50X Stringent Wash concentrate (Bottle 2), was dispensed 
into each 50ml of deionized water. Any unused diluted 
solution was discarded. The stringent wash concentrate 
provided made 1500 ml of diluted solution. 
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SPECIMEN COLLECTION AND PREPARATION 
The reagents and procedures used in this kit were 
optimized for DNA-DNA hybridization using tissues that have 
been routinely processed using buffered formalin and 
embedded in paraffin. 
A. Tissue processing 
Fixation times in buffered formalin should be 24 hrs or 
less; prolonged fixation can result in decreased specific 
staining and elevated background staining. It is 
recommended that fixation times be standardized to 
minimize tissue variability. 
In this case, tissues were formalin-fixed, paraffin-
embedded, but fixation times were unknown. 
B. Tissue sectioning and mounting 
Tissue sections were cut 3 microns thick. The aggressive 
digestion and heating steps used in the DNA "in situ" 
procedure require that tissue sections be well adhered to 
the glass slides; slides were coated with 
organosilane. The procedure for the coating of normal 
slides with organosilane was as followed: 
Clean slides were immersed in 2% solution of 3-
aminopropyl-triethoxysilane in acetone for 2 minutes. 
Rinsed twice in distilled water and air dried. After 
dried, coated slides were baked for 30 minutes at 60°C, 
to ensure optimal adhesion of the sections to the slides 
and stored at room temperature in a dust-free container. 
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PROCEDURE 
In Situ hybridization procedure for double-stranded DNA 
probes and formalin-fixed, paraffin-embedded tissues: 
Prior to beginning the procedure, the pepsin/HCI reagent was 
prepared and pre-warmed to 37°C. 
TBS was prepared and dispense into 4 baths of 250 ml each. 
A heating block was pre-warmed to 90°C. 
All instructions were read thoroughly, with particular 
attention to incubation times and temperature. 
A. De-paraffinization 
Slides with tissue sections were warmed in a 60°C oven 
for 30 minutes. 
Sections were immersed in two changes of xylenes, for 5 
minutes. Sections were immersed in two changes of 100% 
alcohol, followed by three changes of 95% alcohol, for 
one minute each. Sections were then rinsed in two changes 
of deionized water for 3 minutes each. 
B. Tissue Digestion 
The conditions listed below were optimized for tissues 
that have been fixed according to DAKO recommendations. 
over-fixed tissues may require longer digestion times in 
order to achieve adequate staining. 
Sections were immersed in pre-warmed pepsin-HCI for 15 
minutes at 37°C, (digestion conditions may need to be 
tailored to the particular tissue used). 
Sections were washed in two changes of distilled water 
for 5 minutes. 
Slides were removed from water and excess water wiped 
from around each tissue section. 
c. Denaturation and Hybridization 
One drop from each probe of hybridization solution was 
applied to the tissue section. A coverslip was placed 
over the tissue and hybridization solution, taking care 
not to introduce bubbles under the coverslip. 
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The slides were laid on a flat heating block which had 
been pre-warmed to 90°C. The slides were oriented with 
the coverslips facing up and with the tissue sections 
directly over the heating surface. Sections were heated 
for 5 minutes at 90°C to denature the probe and target 
DNA. A 90°C oven may also be used for this step; resting 
the slides on a metal tray or shelf is recommended to 
ensure efficient heat transfer to the slides when using 
an oven. 
After denatured, the slides were transfered from the 
heating block to a pre-warmed humid chamber, and 
incubated at 37°C to hybridize the probe to the target 
DNA. The required incubation period will depend on the 
probe concentration used, and may vary from one to twelve 
hours. At this point the stringent wash was prepared and 
pre-warmed to the appropriate temperature in a water 
bath. 
o. Detection Procedure 
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The tissues can not be allowed to dry during the 
detection procedure, since this would alter the 
hybridization signal. The slides were removed from the 
humid chamber and immersed in a TBS bath for 5 minutes. 
Slides were soaked in the TBS solution in coplin jars, 
until the coverslips slided off of the slides. The slides 
were immersed in a fresh TBS bath for 2 minutes in coplin 
jars. 
The slides were immersed in the pre-warmed stringent wash 
solution in coplin jars and incubated at the appropriate 
temperature, (refer to page 70: Reagent Preparation) for 
30 minutes. The slides were immersed in a fresh TBS bath 
in coplin jars for 1 minute. The slides were removed from 
the TBS and carefully excess fluid wiped off from around 
the sections. The slides were placed on a level surface 
and enough Streptavidin-AP reagent was applied to each 
section to completely cover the tissue and incubated for 
20 minutes at room temperature. The Streptavidin-AP 
reagent was poured off from each slide and slides were 
immersed in a fresh TBS bath for 5 minutes, in coplin 
jars. The slides were removed from the TBS and carefully 
excess fluid was wiped off from around the sections. The 
slides were placed on a level surface and enough of the 
BCIP/NBT substrate solution was applied to each section 
to completely cover the tissue and the slides were 
incubated in the dark at room temperature. The time 
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required for substrate development will vary with target 
concentration. High copy targets are usually 
visualized in 60 minutes or less; low target 
concentrations may necessitate the use of longer 
substrate incubations. If long incubations are used, it 
is recommended that the reaction be monitored each hour 
to avoid over-staining. In this case the slides were 
incubated for 60 minutes. The substrate solution was 
poured off from each slide and slides were immersed in 
deoionized water bath for 5 minutes. 
In this case, slides were not counterstained or mounted in 
permanent media to avoid any possibility of loss of the 
positive signal and/or misinterpretation of the signal. If 
desired, tissues may be counterstained by immersing slides 
in Nuclear Fast Red for 1-2 minutes, followed by a rinse in 
distilled water for 1 minute. And mounted with permanent 
(non-aqueous) media, by immersing the slides for one minute 
each in 95% and 100% alcohols followed by 1 minute in 
Histoclear or xylenes. When using aqueous mounting media, 
slides should be mounted directly without dehydration. 
NOTES ON THE PROCEDURES 
Tissue sections should not be allowed to dry out once the 
hybridization procedure has been started. Sections that are 
allowed to dry will exhibit elevated levels of background 
staining. 
The incubation times and temperatures specified in the kit 
instructions are critical for successfully using this 
procedure. Any change in the procedure may result in 
decreased performance of the assay. 
The color of the positive signals produced by the BCIP/NBT 
reaction had a purple hue, and background may be more 
prominent when tissues are mounted with aqueous 
mounting media. 
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Mounting with permanent media will result in bluer reaction 
signals and very low background levels, but some signal may 
be lost during the tissue dehydration and clearing steps. 
In order to determine the specificity of the hybridization 
reaction, a biotinylated probe of irrelevant specificity may 
be used as a negative control (i.e. DAKO Negative Control 
[plasmid DNA] Biotinylated DNA Probe, Code No. X1102 was 
used). 
A positive control probe is useful for determining the 
suitability of tissue fixation for "in situ" hybridization. 
DAKO Positive control (Human DNA) Biotinylated DNA probe, 
Code No. XllOl, was used to demonstrate genomic DNA in the 
nuclei of human tissues. The specificity of the detection 
reagents can be demonstrated by carrying out the 
hybridization procedure in the absence of probe; the 
presence of background using this control is indicative of 
either high levels of endogenous biotin in the tissue, or 
nonspecific binding of the detection reagents. The latter 
problem may occur if the sections are allowed to dry out 
during the detection procedure. 
LIMITATIONS OF THE ASSAY 
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Negative results may be caused by a variety of procedure 
factors, such as improper tissue fixation, mishandling of 
reagents or performing incubations at improper temperatures. 
Target sequences which exist only at very low copy numbers 
may go undetected. In some instances, binding of 
streptavidin to endogenous biotin within tissues may 
contribute to high background. Liver, kidney, and highly 
proliferative tissues or cells often exhibit high levels of 
endogenous biotin. 
The stringency of hybridization reactions is dependent upon 
many parameters, including probe specificity and the 
temperature and ionic strength of both hybridization and 
wash solutions. 
INTERPRETATION OF STAINING 
Positive signals, corresponding to areas of hybridization, 
appeared as blue or blue-purple regions within individual 
cells of the tissue. Overdevelopment of the substrate 
chromogen may result in black signals. 
Counterstaining with nuclear counterstains may make the 
interpretation of positive signals difficult if too much 
counterstain is used. The use of hematoxylin is not 
recommended, since the blue color of the positive reaction 
is easily obscured by the blue counterstain. A light 
counterstain of the tissue section using Nuclear Fast Red is 
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recommended if additional morphological detail is desired. 
Note: The entire procedure was performed according to DAKO 
In Situ Hybridization Detection System for 
Biotinylated Probes K601 and K602 and adapted to this 
investigation. 
RESULTS 
As indicated in TABLE A, 63 of 100 papillomas evaluated 
by the Avidin-Biotin-Peroxidase Complex method, which showed 
either nuclear or nuclear and cytoplasmic staining, were 
considered as positive. 
Papilloma virus antigen was detected in stratum corneum in 1 
case; in stratum granulosum in 35 cases; in stratum corneum 
and granulosum in 7 cases; in stratum corneum and granulosum 
and upper stratum spinosum in 3 cases; in stratum granulosum 
and upper stratum spinosum in 17 cases. 
Positivity of the staining reaction was noted as a brown to 
dark brown precipitate in the nuclei and cytoplasm, but 
cytoplasmic staining without nuclear staining was not taken 
as positive. Labelling of the cytoplasm can occur due to 
fragmentation of infected nuclei and release of virus 
particles and virus-associated proteins into the cytoplasm, 
or due to non-specific reactivity of cytoplasmic substances 
with HPV antibodies. 131 
The 63 cases that stained positively for the papilloma 
virus antigen were tested by "in situ" hybridization. A wide 
spectrum probe (WSP) which targets HPV DNA of types 6, 11, 
16, 18, 31, 33, 30, 35, 45, 51 and 52 was used. Of these 63 
specimens 39 yielded positive results under intermediate 
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stringency (48° C). 
The 39 cases that were positive with the WSP were, in 
turn, tested individually, each with the type specific 
probes (TSP), under conditions of high stringency (58° C), 
yielding the following results, (APPENDIX C): 
HPV type 6 positive, 7 papillomas. 
HPV type 11 positive, 2 papillomas. 
HPV type 16 positive, O papillomas. 
HPV type 18 positive, 2 papillomas. 
HPV type 31 positive, 10 papillomas. 
HPV type 33 positive, 3 papillomas. 
HPV types 6 and 11 positive, 2 papillomas. 
HPV types 6 and 31 positive, 5 papillomas. 
HPV types 6 and 33 positive, 1 papilloma. 
HPV types 11 and 31 positive, 2 papillomas. 
HPV types 18 and 33 positive, 1 papilloma. 
HPV types 11, 31 and 33 positive, 1 papilloma. 
HPV types non-conclusive results, 3 papillomas. 
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As indicated in TABLE B and APPENDIX B, the following 
reactivity were seen with the TSP: 
HPV type 6 probe, 15 cases were strongly positive, 5 
were moderately positive and 8 weakly positive. 
HPV type 11 probe, 6 cases were strongly positive, 2 
were moderately positive and 1 weakly positive. 
HPV type 16 probe, none of the cases were strongly 
positive, 2 were moderately positive and 4 weakly 
positive. 
HPV type 18 probe, 2 cases were strongly positive, 1 
moderately positive and 6 weakly positive. 
HPV type 31 probe, 17 cases were strongly positive, 5 
moderately positive and 2 weakly positive. 
HPV type 33 probe, 5 cases were strongly positive, 3 
moderately positive and 7 weakly positive. 
Multiple strong hybridization signals with the 
following HPV type probes: 
HPV type 6 and 11 probes, 2 cases. 
HPV type 6 and 31 probes, 5 cases. 
HPV type 6 and 33 probes, 1 case. 
HPV type 11 and 31 probes, 2 cases. 
HPV type 18 and 33 probes, 1 case. 
HPV type 11, 31, and 33 probes, 1 case. 
Two of the cases belonged to a same patient, being the two 
papillomas strongly positive with HPV type 11 probe and 
moderately positive with HPV type 31 probe. 
Multiple moderate signals were seen in 1 case which 
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reacted with probe 18. Multiple weak signals were seen in 2 
cases, one reacted with probes 6, 31, 18 and others with 
probes 31 and 33. The results for these cases were recorded 
as non-conclusive (NC). 
Positivity of the staining reaction was noted as a 
blue-purplish or black precipitate in the nuclei of the 
infected cell. In some cases of tissues that contained high 
amounts of DNA, the stain spread from the nuclei into the 
surrounding spaces. However, cytoplasmic staining in the 
absence of nuclear staining was not interpreted as positive. 
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This was seen in 6 cases. 
Positive staining occurred in cells with pyknotic ovoid 
nuclei, crescent-shaped or flat elongated nuclei which could 
be compressed against the cell membrane and small or 
enlarged centered or wrinkled nuclei, but these 
characteristic could also be seen in negative cells. 
Staining intensity varied from weak (pale blue-purple) 
to strong (dark blue-purple or black). 
Staining patterns of nuclei were based on the following 
criteria, according to Enzo PathoGene DNA Probe Assay for 
Identification of Human Papillomavirus (Catalog No. PG-877), 
Interpretation Guide: 
a. Full nuclear staining, nucleus appeared completely filled 
with stain. 
b. Granular or stippled nuclear staining, nucleus appeared 
filled with granules or dots. 
c. Mixed nuclear staining, the nuclei of some cells appeared 
fully stained, while the nuclei of others showed a 
granular or stipped staining. 
Reactions with the WSP were either considered positive or 
negative. A weak, moderate or strong nuclear staining was 
considered as positive. 
Reactions for TSP were considered as positive, inconclusive 
or negative based on the intensity of the hybridization 
signal: 
1. Positive, a strong hybridization signal, when nuclear 
staining was dark, same as control slide and a moderate 
hybridization signal, when the signal was lighter than 
control slide but darker than the weaker hybridization 
signal. 
2. Non-conclusive, only weak or moderate hybridization 
signals with more than one probe. 
3. Negative, absence of nuclear staining. 
Nuclear staining was confined to single cells localized in 
certain areas of the epithelium or clusters of cells 
localized or diffused throughout the epithelium. 
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Weak multiple hybridization signals of the same 
papilloma with different specific probes were considered 
negative since according to the manufacturer (DAKO 
Corporation), this may be indicative of cross reactivity 
with other HPV types in the tissues which contains very high 
amounts of HPV DNA. HPV type is determined in these cases by 
comparison of the signal intensities resulting from the 
individual probes. The strongest hybridization signal was 
the one considered as positive. 
Positive and negative controls showed no equivocal 
results and no signs of cross hybridization. 
All positive controls were strongly positive for each of the 
probes. 
Specimens that were strongly positive for HPV types 6, 
11 and moderately positive for HPV type 16 showed nuclear 
staining in cells of stratum granulosum and upper stratum 
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spinosum. 
Specimens that were strongly and moderately positive for HPV 
type 18, staining of nuclei was confined to stratum 
granulosum and spinosum in 2 cases and one case also showed 
reactivity in the stratum basale. 
Specimens that were positive for HPV types 31 and 33 
exhibited a multi-layered pattern of reactivity, in these 
cases staining was seen in stratum granulosum, spinosum and 
basale. 
Based on the histomorphological description, a 
comparison of papillomas positive and negative with the wide 
spectrum probe (WSP) showed the following results: 


















































Koilocytosis varied from huge koilocytic cells to small 
koilocytic cells which could either be localized or sparsed 
through the epithelium. 
DISCUSSION AND CONCLUSIONS 
The main objective of this study was to detect the 
presence of HPV types 6, 11, 16, 18, 31 and 33 in oral 
squamous papillomas. This was accomplished through the use 
of two different methods, the Avidin-Biotin-Peroxidase 
Complex for the immunohistochemistry technique and "in situ" 
hybridization. 
Papillomavirus antigen was detected in 63% (63/100) and 
HPV DNA in 61% (39/63) of the papillomas which were tested 
with the Wide Spectrum Probe, while 38% (24/63), were 
negative for HPV DNA. 
The majority of the papillomas, were infected with HPV 
type 31 DNA, 25% (10/39); followed by HPV type 6 DNA, 17% 
{7/39); HPV types 6 and 31 DNA, 12% (5/39); HPV type 33 DNA, 
7% (3/39), HPV type 11, 5% (2/39); HPV types 6 and 11 DNA, 
5% (2/39); HPV types 11 and 31 DNA, 5% (2/39); HPV type 18 
DNA, 5% (2/39);HPV types 6 and 33 DNA,(1/39): 2% HPV types 
18 and 33 DNA, 2% {l/39); HPV types 11, 31 and 33 DNA, 2% 
(1/39). None of the cases expressed HPV type 16 DNA and 3 of 
the cases showed non-conclusive results, {APPENDIX C). 
Oral lesions with no evidence of viral antigen and/or 
DNA may: 
1. Be a non-viral associated tumor, a normal anatomic 
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variant or a papillary hypertrophy resulting from long 
standing inflamatory disease. 132 
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2. Be a new HPV genotype with a nucleotide sequence that 
does not cross hybridize with the probes employed in this 
study. 
3. Represent HPV-associated lesions with a viral copy number 
below that detectable by the "in situ" hybridization 
technique. 
4. Have been virally initiated with subsequent shedding of 
infected cells through epithelial proliferations and 
maturation. 133 
5. Have been originally present but lost during the harsh 
treatments of the procedure. 
Based on the findings of this investigation, a 
histomorphological description of the papillomas which 
express HPV DNA and those papillomas which do not express 
HPV DNA was performed, in order to establish a correlation 
between histology and molecular hybridization findings. 
It is believed, that papillomavirus (PV) induce changes in 
the epithelium which reflect their biological behavior. PV 
induced lesions display features of acanthosis, dysplasia, 
dyskeratosis, hyperchromasia, hyperkeratosis, koilocytosis 
and basal cell replication. These cytologic changes are 
associated with virus production, which result in the death 
of the infected cell as the virus multiply in the nucleus 
and the level where these cytopathic changes begin is 
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determined by the virus type. 134 
PV affects the keratinocyte metabolism, changes in 
keratin composition are seen in a variety of epidermal 
disorders and these changes seem to correlate with the 
degree of hyperplasia in the lesion. The most common finding 
is the decrease in the relative amount of 67K keratin. 135 
Acanthosis and basal cell proliferation, is thought to occur 
due to the presence of HPV DNA in the basal cell layer. In 
common warts, autoradiography with tritiated thymidine has 
shown an increase in DNA synthesis in basal and parabasal 
cells, two to three layers above the basement membrane136 
and juvenile laryngeal papillomas in parabasal cells 
extending nearly to the surface.u7 Also, basal cell 
hyperplasia, is thought to be due to an early gene 
expression of the HPV ocurring prior to vegetative viral DNA 
synthesis. In contrast, the synthesis of viral capsid 
proteins appear to be a function of late gene expression 
since it occurs only in terminally differentiated squamous 
cells in the superficial layers. 138 
PVs seem to have a predilection for specific sites of 
the epithelium rather than being specific for a particular 
lesion. This tissue-specificity may reflect a requirement 
for cellular factors present in keratinocytes. PV subtypes 
may have evolved by adapting to different patterns of 
keratinocyte differentiation found in specific 
epi thel ia. 139 
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HPVs 6, 11, 13, 16, 18 and 32, the types that most commonly 
infect the oral mucosa, share a degree of sequence homology 
with each other and these homologous regions might play a 
role in tissue-specific infection. The above might explain 
the fact, that similar HPV types have been detected in 
clinically and histomorphologically different lesions, 
except for types 13 and 32. These types are mainly seen in 
Focal Epidermal Hyperplasia, (FEH) and have only been 
detected in oral mucosa and perioral skin, as well as in a 
small percentage of Condyloma Acuminatum, (CA) and Squamous 
Cell Papillomas (SCP). Lesions which contain HPV types 13 
and 32 show FEH-like characteristics, such as hyperpara-or 
hyperorthokeratosis, increased cellular density, acanthosis, 
unusual rete pegs that demonstrate clubbing and horizontally 
anastomosing outgrowths, koilocytes, mitosis-like nuclear 
degeneration, swollen cells with ballooning type of nuclear 
degeneration. 
Immunoregulation plays a role in the pathogenesis of HPV 
induced lesions, since they predispone the individual to 
uncommon types and to develop lesions with an unusual 
clinical apperance."0 
In the genital tract, proliferations induced by viral 
types 6, 11 and 31, preserve characteristics of regular 
differentiation pattern, the nuclei are regularly shaped and 
the DNA content is tetraploid or diploid. 141 While, 
proliferations caused by types 16 and 18, are characterized 
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by marked nuclear atypia, regular and atypic mitotic figures 
even in the upper third of the epithelial layer, an 
aneuploid karyotype and a low number of koilocytotic cells 
which may be entirely absent. 142 Also, they seem to regress 
less and recurr more frequently than those proliferations 
cause by HPV types 6 and 11. Common warts regressing more 
frequently than condyloma acuminatum. In general, PV-induced 
proliferations of the genital tract are caracterized by long 
duration and frequent recurrence, even after surgical 
removal . 143 
The majority of HPV induced lesions in skin and mucosa 
regress spontaneously but a certain number progress to 
malignancy. HPV types 6 and 11 are considered to cause 
benign lesions, while HPV types 16 and 18 are considered to 
have oncogenic potential. Thus, lesions caused by these 
types are considered malignant, or at least pre-malignant. 
HPV type 18 seems to produce a more invasive type of lesion 
than HPV type 16. Their role in neoplastic transformation is 
clearly seen in Epidermodysplasia Verruciformis (EV) and 
ano-geni tal carcinomas. 144 In the oral cavity, there is a 
report of leukoplakias transforming into squamous cell 
carcinomas. 145 
The ability of certain HPV types for malignant 
transformation seems to be related to two transforming 
proteins encoded in their genome, which bind to the tumor 
suppressor gene of the cell, providing a mechanism for HPV 
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induced cervical neoplasm. 146 Or, there could be a genetic 
lack or malfunction of the tumor suppressor gene, thus 
allowing the virus to control the replication mechanisms of 
the epithelial cells and start replicating itself. Repeated 
studies have demonstrated that the majority of cervical 
cancers and derived cell lines contain HPV DNA. But not all 
cells infected with the virus undergo malignant 
transformation because the malignant tumors are monoclonal, 
while the HPV lesions are not. 147 ·148 
In the etiology of cancer, there seems to be a need for 
cofactors which act with the virus in order to produce the 
malignant transformation, because usually the time elapsed 
since the time of infection and the onset of cancer could be 
decades. 149 In the oral cavity, such co-factors could be 
alcohol, chewing tobacco, cellular mutations, heredity, 
radiation, smoking and in the skin, also, sunlight. Such is 
the case in EV, where skin lesions containing HPV types 5 
and 8 become malignant after being exposed to sunlight. 
HPV infection is transmissible and the virus is highly 
contagious. Since it has no envelope, the virus is resistant 
to either inactivation, freezing and dessication, therefore 
remains infectious after drying . 150 
The majority of the papillomas which expressed HPV DNA 
with the Wide Spectrum Probe (WSP), showed parakeratin 41% 
(16/39), followed by hyperparakeratin 20% (8/39) and ortho-
parakeratin 20% (8/39), hyperorthokeratin 7% (3/39), 
combination of hyperpara/parakeratin 5% (2/39) and 
orthokeratin 5% (2/39). 
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Of the papillomas which did not expressed HPV DNA with the 
WSP, the majority showed hyperparakeratin 37% (9/24), 
followed by parakeratin 29% (7/24), orthokeratin 16% (4/24), 
hyperorthoparakeratin 8% (2/24), hyperorthokeratin 4% (1/24) 
and combination of hyperortho/orthokeratin 4 % (1/24). 
Acanthosis was seen in 89% (35/39) of the papillomas 
which expressed HPV DNA and in 87% (21/24) of the papillomas 
which do not expressed HPV DNA. 
Basal cell layer replication was seen in 87% (34/39) of 
the papillomas which expressed HPV DNA and in 66% (16/24) of 
the cases which did not expressed HPV DNA. 
Dyskeratosis (benign) was only seen in 2 of the 
papillomas which expressed HPV DNA 5% (2/39). 
Koilocytosis was seen in 87% (34/39) of the papillomas 
which expressed HPV DNA and in 58% (14/24) of the papillomas 
which did not expressed HPV DNA. 
Basal cell mitotic activity was seen in 12% (5/39) of 
the papillomas which expressed HPV DNA and in 8% {2/24) of 
the papillomas which did not expressed HPV DNA. Suprabasal 
cell mitotic activity was seen in 5% (2/39), of the 
papillomas which expressed HPV DNA and in 12% (3/24) of the 
papillomas which did not expressed HPV DNA. 
Nuclear hyperchromasia in basal cells was seen in 2% 
(l/39), prominent nucleoli in basal cells were seen in 2% 
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(1/39), multiple nucleoli in basal and suprabasal cells were 
seen in 2% (1/39), of the papillomas which expressed HPV 
DNA. Prominent nucleoli in basal cells were seen in 4% 
(1/24) of the cases which did not expressed HPV DNA, 
(APPENDIX D and E). 
Nuclear shape varied in cells which expressed HPV DNA. 
Positive staining occured in cells with pyknotic ovoid 
nuclei, crescent-shaped or flat elongated nuclei which could 
be compressed against the cell membrane, wrinkled nuclei and 
small or large centered nuclei. 
Varying degrees of papillomatosis, were seen in all 
papillomas. 
Thus, different forms of keratinization, acanthosis, 
koilocytosis, papillomatosis, basal and suprabasal cell 
replication, basal and suprabasal mitotic activity were seen 
in papillomas whether or not they expressed HPV DNA. 
As shown in this study, hyperkeratinization is not 
pathognomonic of HPV infection. But in the oral cavity, 
keratinization present in papillomas located in areas of 
normally non-keratinizing epithelium such as ventral surface 
of the tongue, floor of the mouth, vestibular mucosa and 
tonsils, is abnormal. 
Koilocytosis and parakeratinization were the most prominent 
features of HPV infected papillomas. Thus, in the oral 
cavity koilocytosis and parakeratinization are caracteristic 
of the presence of HPV DNA, according to the results of this 
investigation. 
The type of HPV determines its location in the 
epithelium. HPV types 6, 11, 16 DNA were only detected in 
the most superficial layers of the epithelium , while HPV 
types 31 and 33 were also detected in stratum basale. HPV 
type 18 DNA, was detected in one papilloma in the stratum 
granulosum, spinosum and basale. 
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A papilloma can be infected with more than one type of 
HPV based on the most recent investigation using an improved 
technique for Polymerase Chain Reaction (PCR) . 151 
Single infection was seen in 24 papillomas which reacted 
strongly with only one probe (6, 11, 18, 31, 33). Dual 
infection was seen in 11 papillomas where there was a strong 
reaction with two different probes (6 and 11; 6 and 31; 6 
and 33; 11 and 31; 18 and 33 ). A triple infection was seen 
in a papilloma which reacted strongly with probes 11, 31 and 
33, (APPENDIX A). 
There were two cases of multiple weak positive signals and 
one with multiple signals which were regarded as non-
conclusive. 
The multiple weak or moderate signals present in the same 
papilloma could have been caused by: 
a. Cross-hybridization between the probe and viral DNA 
sequences. 152 
b. Very low DNA number copies present in the specimen 
weakly detected by the probe. 
c. Presence of a diferent type of virus from the type 
being tested by the type specific probe (TSP) but 
target by the wide spectrum probe (WSP). 
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d. Type of solution used to fix the tissue and fixation 
times will affect the intensity of the hybridization 
signal, reducing it even to undetectable levels. 153 
e. Strong homology between HPVs, such in the case of 
HPV types 6 and 31 that causes cross hybridization 
between these two types . 154 
A risk profile for malignancy could be established 
according to the type of HPV present. 
Papillomas infected with HPV types 6 and 11 are considered 
"low risk". Although, there has been reports of laryngeal 
papillomas positive for HPV type 6, progressing to 
pharyngeal carcinomas, 155 but it could have been caused by 
an undetected HPV, belonging to the types considered 
oncogenic. 
Papillomas infected with HPV types 31 and 32 are considered 
"intermediate risk", and papillomas infected with HPV 16 and 
18, are considered "high risk". 
Typing should be done of all oral squamous papillomas 
because of the oncogenic potential of some HPV types and 
patients should be closely monitored. And also, because of 
statitical and histopathological evidence suggesting that 
condylomata which may exist as a sub-clinical PV infection 
and cervical intraepithelial neoplasm (CIN), represent the 
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extremes of a single disease spectrum. 156 
The above could also be applied to the oral cavity. Oral 
squamous papillomas (including oral condyloma acuminatum and 
oral verruca vulgaris}-leukoplakia-oral verrucous 
carcinomas-oral squamous carcinomas could all be part of a 
same disease spectrum, since the same HPV DNA types have 
been detected in these lesions. 
In the oral cavity, all papillomas, whether they 
exhibit the same clinical and histomorphological 
caracteristics of its counterpart in the ano-genital region 
(Condyloma Acuminatum} or its counterpart in the skin 
(Verruca Vulgaris}, should be considered variants of the 
same disease entity. Therefore, base on the findings of this 
investigation and in the characteristics observed in the 
majority of the cases assayed, oral squamous papillomas 
could be re-defined as: 
Oral squamous papillomas are composed of keratinized, 
acanthotic, stratified squamous epithelial ridges, disposed 
in papillary projections with basal cell layer replication 
and a fibrous or fibrovascular supporting stroma. The 
epithelial ridges could be elongated, short, broad, fused or 
not. The papillary projections could be sharp or blunt. The 
overlying epithelium is mainly parakeratinized, but it could 
also be hyperparakeratinized, orthokeratinized, 
hyperorthokeratinized, or a combination of para-
orthokeratin. Koilocytosis, dyskeratosis, dysplasia might be 
present or not. 
The diagnosis of Oral Squamous Papillomas, would be 
made based on whether or not they express viral DNA and 
whether or not they exhibit characteristics of Condyloma 
Acuminatum or Verruca Vulgaris: 
HPV DNA positive papillomas, with caracteristics of 
Condyloma Acuminatum, would be diagnosed as "Oral 
Squamous Papillomas of viral origen, compatible with 
Condyloma Acuminatum." 
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HPV DNA positive papillomas, with characteristics of 
Verruca Vulgaris, would be diagnosed as "Oral Squamous 
Papillomas of viral origen, compatible with Verruca 
Vulgaris." 
HPV DNA positive papillomas, which do not present 
characteristics of Condyloma Acuminatum or Verruca 
Vulgaris would be diagnosed as "Oral Squamous 
Papillomas of viral origin". 
HPV DNA negative papillomas, would be diagnosed as 
"Oral Squamous Papillomas of non-specific origin." 
Based on the above re-definition, the present confusion 
that exists regarding the diagnosis of oral squamous 
papilloma, condyloma acuminatum, and/or verruca vulgaris 
could be eliminated if all these lesions were considered as 
papillomas in the oral cavity, whether they exhibit 
characteristics of condyloma acuminatum or verruca vulgaris. 
HPV types 6, 11, 16, 18, 31, 33 infect the oral mucosa 
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as have been shown in this investigation. Whether, transient 
or permanent hosts of the oral cavity, they cause papillary 
lesions of the epithelium. And, as DNA hybridization 
techniques for detection of HPV improve and other more 
sensitive techniques develop, more oral squamous cell 
papillomas will be found to harbor HPV DNA. 
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TABLE A 
PAPILLOMAS CASE SELECTION AND RESULTS 
CASE NO. AGE/SEX LOCATION BPV-1 WSP TSP 
1335-92 31/M Hard Palate -
1277-92 29/F Hard Palate + -
1227-92 36/F Soft Palate + + 33 
1093-92 40/F Hard Palate + -
1090-92 50/M Lower Lip + -
996-92 40/F Ginqiva # 8 -
717-92 12/F Lower Lip + -
689-92 40/F Soft Palate -
567-92 41/M Vermillion Lip + -
564-92 32/M Lower Lip + + 6 
492-92 28/M Lingual Frenum + + 31 
461-92 44/M Buccal Mucosa + -
236-92 36/M Buccal Mucosa + + 6 
214-92 57/M Floor Mouth + + 6,11 
1040-90 36/M Submax. Duct -
1065-90 32/M Uvula + -
799-90 52/F Vermillion Lip + + 18,33 
670-90 25/M Buccal Mucosa + + NC* 
464-90 64/F Tip Tonque + -
424-90 64/M Alveolar Ridge -
242-90 55/F Lateral Tongue + + 18 
1067-1-89 65/F Buccal Mucosa + + 31 
1060-89 29/M Soft Palate -
100 
869-89 63/M Lingual Fr en um + + 6,33 
780-89 52/M Ventral Tongue + + 11,31 
734-89 54/M Labial Mucosa + + 18 
713-89 81/F Buccal Gingiva + -
674-89 17/M Gingiva + + 31 
657-89 30/M Soft Palate + + NC 
656-89 77/M Hard Palate -
645-89 17/M MGJ* + + 11,31 
637-89 38/F FM-BT* + + 11,31,33 
377-89 8/F Unknown -
285-89 28/F Area # 13 + + 33 
174-89 NK*/M Soft Palate + -
191-89 47/F Tongue -
131-89 73/M Tip Tongue + + 31 
129-89 NK/M Lower Lip -
71-89 65/F Soft Palate + + 31 
1050-88 32/M Dorsal Tongue -
980-88 62/F Ventral Tongue -
970-88 50/M Soft Palate + + 6 
934-88 53/F Hard Palate + + NC 
834-87 10/F Retromolar Pad -
735-87 45/M Dorsum Tongue + + 31 
628-87 NK/F Buccal Gingiva -
189-87 51/F Tip Tongue + -
13-87 53/M Floor Mouth -
1106-86 57/M Buccal Mucosa + + 6,31 
843-86 41/M Buccal Mucosa -
798-86 51/F Lateral Tongue + + 31 
789-86 56/M Tonsil Pillar -
765-86 55/M Lingual Gingiva + + 6 
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798-86 51/F Lateral Tongue + + 31 
789-86 56/M Tonsil Pillar -
765-86 55/M Lingual Gingiva + + 6 
578-86 62/M Uvula + -
524-86 25/F Buccal Mucosa -
485-86 25/F Tip Tongue + + 31 
356-86 36/M Tuberosity -
287-86 67/F Soft Palate -
1065-85 33/M Unknown + -
962-85 41/M Buccal Mucosa + + 6 
902-85 NK/M Comissure Lip + + 6,31 
892-85 NK/M Retromolar Pad + -
816-A-85 NK/M Alveolar Ridge + + 11 
816-B-85 NK/M Lingual Frenum + + 11 
782-85 49/M Dorsum Tongue + + 6,31 
627-85 32/F Tip Tongue + -
479-85 26/M Dorsal Tongue + + 6,31 
481-85 63/M Tonsilar Pillar + -
228-85 47/F Tongue + -
341-85 41/F Ventral Tongue -
268-85 37/M Hard Palate + -
160-85 33/M Ventral Tongue + + 6 
333-84 27/M Buccal Mucosa -
240-84 63/F Gingiva # 2 -
698-83 54/F Lateral Tongue -
682-83 58/M Dorsum Tongue -
655-83 38/M Mucosa Lip + + 6,11 
623-82 60/M Palate + + 31 
244-82 62/F Upper Lip + + 6,31 
216-82 63/F Buccal Mucosa -
153-82 NK/F Hard Palate 
143-82 NK/F Alveolar Ridqe 
142-82 53/F Alveolar Ridge 
728-81 30/M Mucosa Cheeck 
620-81 NK/M Lateral Tonque 
387-81 35/M Lower Lip 
200-80 60/F Palate 
202-79 30/F Hard Palate 
165-79 38/M Hard Palate 
213-78 6/F WOP* 
193-78 42/F Vermillion Lip 
155-78 23/M Lingual Frenum 
532-77 56/M Hard Palate 
454-77 27/M Retromolar Pad 
410-75 25/M FM-BT 
315-75 NK/F Papilla Max. 
823-74 NK/M Unknown 
1002-70 50/M , Lower Lip 
785-70 5/F Gingiva 
557-70 56/M Soft Palate 
* NC: Non-conclusive 
* MGJ: Muco-Gingival Junction 
* FM-BT: Floor Mouth-Base Tongue 
* NK: not known 
* WOP: Wharton's Duct Papilla 
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BPV TYPE SPECIFIC PROBE REACTIVITY 
CASE HPV-6 HPV-11 HPV-16 HPV-18 HPV-31 HPV-33 
1227-92 + + +++ 
564-92 +++ 
492-92 + + +++ 
236-92 +++ 
214-92 +++ +++ 
799-90 + ++ ++ 
670-90 + + 
242-90 + +++ 
10671-89 +++ 
869-89 +++ + +++ 
780-89 ++ +++ +++ ++ 
734-89 + + +++ ++ + 
674-89 ++ +++ 
657-89 ++ ++ + ++ ++ 
645-89 ++ ++ 
637-89 ++ +++ + + +++ +++ 
285-89 ++ +++ 
131-89 +++ 
71-89 + + +++ + 
970-88 +++ 
934-88 + I + + 
735-87 + ++ +++ + 














+ Weakly reactive 
++ Moderate reactive 
+++ Strongly reactive 
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FIGURE 1: HPV Type Wide Spectrum Positive Control 
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FIGURE 2: HPV Type Wide Spectrum Positive Papilloma 
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FIGURE 3: HPV Type 6 Positive Control 
FIGURE 4: HPV Type 6 Positive Papilloma 
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FIGURE 5: HPV Type 11 Positive Control 
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FIGURE 6: HPV Type 11 Positive Papilloma 
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FIGURE 7: HPV Type 18 Positive Control 
• 
FIGURE 8: HPV Type 18 Positive Papilloma 
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FIGURE 9: HPV Type 31 Positive Control 












































TYPE SPECIFIC PROBE REACTIVITY 
HPV Type Weak Moderate strong 
6 8 5 15 
11 1 2 6 
16 4 2 0 
18 6 1 2 
31 2 5 17 
33 7 3 5 
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APPENDIX C 
HPV DNA POSITIVE PAPILLOMAS 
HPV Type .Percentage Cases 
31 25% 10/39 
6 17% 7/39 
6, 31 12% 5/39 
33 7% 3/39 
NC 7% 3/39 
11 5% 2/39 
6, 11 5% 2/39 
11, 31 5% 2/39 
18 5% 2/39 
6, 33 2% 1/39 
18, 33 2% 1/39 
11,31,33 2% 1/39 
APPENDIX D 













Suprabasal Cell Mitosis 
HPV 
Basal Cell Nuclear Hyperchromasia 
Basal Cell Prominent Nucleoli 



































HISTOMORPHOLOGY OF HPV DNA NEGATIVE PAPILLOMAS 
Feature 
Acanthosis 





Suprabasal Cell Replication 




Basal Cell Prominent Nucleoli 
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